WO2002016536A1 - Bactericidal antifouling detergent for hard surface - Google Patents

Bactericidal antifouling detergent for hard surface Download PDF

Info

Publication number
WO2002016536A1
WO2002016536A1 PCT/JP2001/006869 JP0106869W WO0216536A1 WO 2002016536 A1 WO2002016536 A1 WO 2002016536A1 JP 0106869 W JP0106869 W JP 0106869W WO 0216536 A1 WO0216536 A1 WO 0216536A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
carbon atoms
weight
acid
component
Prior art date
Application number
PCT/JP2001/006869
Other languages
French (fr)
Japanese (ja)
Inventor
Shin Aihara
Noriyuki Morii
Kazunori Tsukuda
Hiroyuki Yamada
Original Assignee
Kao Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corporation filed Critical Kao Corporation
Publication of WO2002016536A1 publication Critical patent/WO2002016536A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D1/00Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
    • C11D1/38Cationic compounds
    • C11D1/62Quaternary ammonium compounds
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/37Polymers
    • C11D3/3746Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C11D3/3769(Co)polymerised monomers containing nitrogen, e.g. carbonamides, nitriles or amines

Definitions

  • the present invention relates to a cleaning composition for hard surfaces that can disinfect hard surfaces and prevent soiling, that is, prevent adhesion of dirt, and easily remove attached dirt.
  • a cleaning composition for hard surfaces that can disinfect hard surfaces and prevent soiling, that is, prevent adhesion of dirt, and easily remove attached dirt.
  • Conventional technology can disinfect hard surfaces and prevent soiling, that is, prevent adhesion of dirt, and easily remove attached dirt.
  • Conventional technology can disinfect hard surfaces and prevent soiling, that is, prevent adhesion of dirt, and easily remove attached dirt.
  • Japanese Unexamined Patent Publication No. 2-1456977 discloses a flush toilet detergent containing a sulfobetaine-type amphoteric surfactant having a specific structure
  • Japanese Unexamined Patent Publication No. 3-35097 discloses a flush toilet detergent containing a sulfobetaine-type amphoteric surfactant having a specific structure
  • Hei 10-16797 discloses a water-based toilet cleaner containing a sulfosuccinic acid ester, which is excellent in loose stool adhesion and has a high cleaning effect. Detergents to be mixed in proportions are described.
  • Japanese Unexamined Patent Application Publication No. Hei 9-16995 describes that a cleaning agent having a water contact angle of 30 degrees or less with a hard surface after treatment shows excellent antifouling property.
  • an antifouling base a combination of an anionic surfactant with a surfactant containing a quaternary ammonium group in a molecule or a water-soluble polymer is mentioned.
  • An object of the present invention is to provide home use, and in cleaning hard surfaces such as toilets, bathrooms, and kitchen surroundings, not only excellent detergency but also sterilization and antifouling properties can be imparted at a satisfactory level. Agent. Disclosure of the present invention
  • the present invention relates to (a) a compound having a weight-average molecular weight of 1,000 to 6,000, and at least one group selected from a quaternary ammonium group and a tertiary amino group; A polymer having a monomer unit content of 0.1 to 100 mol% with respect to one monomer unit; (b) a sterilizer having a molecular weight of less than 1,000 and having a quaternary ammonium group (CA) / (b) when the surfactant contains (cA) anionic surfactant, and (cA) a surfactant. It is a germicidal and antifouling detergent for hard surfaces not exceeding 1.0 by weight.
  • the present invention relates to a method for cleaning and disinfecting a hard surface by applying the above composition to a hard surface and for preventing the adhesion of dirt to the hard surface. Provide use for preventing the adhesion of dirt to the surface.
  • the component (a) of the present invention is a polymer containing 10 to 100 mol% of a monomer unit having a quaternary ammonium group and / or a tertiary amino group (hereinafter, referred to as a monomer unit A).
  • Monomer unit A is obtained by polymerizing a monomer (hereinafter, referred to as monomer A) containing a quaternary ammonium group (or a plurality of monomers) or a tertiary amino group (or a plurality of monomers).
  • the monomer unit may be a monomer unit obtained by polymerizing a contained monomer (hereinafter, referred to as monomer A ′), or may be a quaternary ammonium obtained by quaternizing a tertiary amino group.
  • the monomer A having a quaternary ammonium group that is, as an example from which the monomer unit A is derived, a compound represented by the following formula (4) can be mentioned.
  • X represents an alkylene group having 1 to 12 carbon atoms , —COOR 18 —, — CONHR 18 —, — OCOR 18 —, — R 19 — ⁇ CO—R 18 — where R 18 and R 19 are each independently carbon An alkylene group having a number of 1 to 5.
  • R 16 has a carbon number
  • R 17 is an alkyl group having 1 to 3 alkyl groups, hydroxyalkyl group, or benzyl group
  • R 17 is an alkyl group having 1 to 10 carbon atoms which may be substituted with a hydroxy group, a carbonyl group, a sulfonic acid group or a sulfate group.
  • Y— represents an anion.
  • R 17 contains a carboxyl group, a sulfonic acid group, or a sulfate group
  • Y— does not exist, and these groups in R 17 become anions.
  • anion of Y— include a halogen ion, a sulfate ion, an alkyl sulfate ion having 1 to 3 carbon atoms, an aromatic sulfonate ion optionally substituted by an alkyl group having 1 to 3 carbon atoms, and a hydroxy ion. Can be mentioned.
  • Preferred examples of the tertiary amino group monomer A ′ that is, a compound derived from a monomer unit ⁇ ′, include a compound represented by the following formula (5). (Five)
  • R l2, R l3, R l R 15 and R 16 are the same as above described.
  • N N-dialkyl (C1-3) aminoalkyl (C1-5) acrylate (or methacrylate), N, N-dialkyl (C1-3) aminoalkyl (C1-5) ) Acrylamide, N, N-di ( ⁇ -alkenyl (C 3 -L 0))- ⁇ -methylamine is preferred, and diarylmethylamine is particularly preferred.
  • quaternizing agents such as methyl chloride, methyl bromide, benzyl chloride, dimethyl sulfate, getyl sulfate, monochloroacetic acid or a salt thereof, chlorsulfuric acid or a salt thereof, and 3-chloro-2 -It is preferably carried out using hydroxypropanesulfonic acid or a salt thereof, ethylene oxide, propylene oxide, or glycidyl ether.
  • ethylene oxide, propylene oxide, or glycidyl ether When ethylene oxide, propylene oxide, or glycidyl ether is used, it is preferable to react after neutralizing the monomer units with sulfuric acid, hydrochloric acid, a carboxylic acid having 1 to 12 carbon atoms, or arylsulfonic acid in advance. .
  • the component (a) of the present invention includes not only a polymer composed of monomer units A (a plurality of types may be used), but also a monomer unit A (a plurality of types may be used) and another monomer unit (hereinafter, referred to as “a”). Or a polymer composed of 6 units. (When monomer A 'is used, it may have an amine type monomer unit.) In this case, the arrangement of monomer unit A and monomer unit B (there may be plural types) , Block, alternating, periodic, statistical (including random), or graft type.
  • the polymer composed of the monomer units A and B can be obtained, for example, by copolymerizing the respective precursor monomers.
  • the monomer unit B is preferably a monomer unit derived from a monomer selected from the following monomer groups (i) to (V), and is preferably a monomer unit derived from the monomers described in (i) to (iii) or (V).
  • a monomer unit is more preferred, and a monomer unit derived from the monomer (i), (ii) or (V) is most preferred, particularly from the viewpoint of antifouling effect.
  • Acrylic acid or a salt thereof methacrylic acid or a salt thereof, maleic acid or a salt thereof, maleic anhydride, styrenesulfonate, sulfopropyl methacrylate, 2-acrylamide-2-methylpropanesulfonic acid or a salt thereof
  • Anion group-containing compounds selected from mono- ⁇ -methacryloyloxyalkyl phosphates (1 to 12 carbon atoms)
  • the polymer having the monomer unit ⁇ and the monomer unit ⁇ may be synthesized by the above-mentioned copolymerization method, or may be formed into a polymer containing the monomer unit A by one of the monomers (i) to (
  • It may be obtained by graft polymerization of the monomers of (i) and (ii), or may be obtained by graft polymerization of the monomer of the general formula (4) to a polymer containing the monomers of (i) to (v). Or a polymer containing the monomers (i) to (V), particularly preferably a polymer containing the monomers (i) and (ii), graft-polymerized with the monomer of the general formula (5). After that, it may be quaternized.
  • the most preferred monomer unit B of the present invention is a monomer having one or more groups selected from a carboxylic acid group and a sulfonic acid group (but not having a quaternary ammonium group), ie, the monomer of the above (i) Monomer unit (hereinafter referred to as monomer unit B ').
  • the polymer constituting the component (a) of the present invention may be obtained by any polymerization method, a radical polymerization method is particularly preferable, and the polymerization can be carried out in a bulk, solution, or emulsion system.
  • Radical polymerization may be initiated by heating, but the initiators are 2,2'-azobis (2-amidinopropane) dihydrochloride and 2,2'-azobis (N, N-dimethyleneisobutylamidine).
  • Azo initiators such as dihydrochloride, and organic peroxides such as hydrogen peroxide and benzoyl peroxide, t-butyl hydroperoxide, cumene hydroperoxide, methylethylketone peroxide, perbenzoic acid, etc.
  • radical initiators such as oxides, persulfates such as sodium persulfate, potassium persulfate, ammonium persulfate, etc.
  • redox initiators such as hydrogen peroxide-Fe 3+ , etc.
  • Polymerization may be started by light irradiation or radiation irradiation in the presence or absence of a compound.
  • the component (a) of the present invention may be a homopolymer of the monomer unit A or a mixture of plural kinds of polymers selected from a copolymer of the monomer unit A and the monomer-unit B.
  • a more preferred constitution in the component (a) of the present invention is that the total of the monomer units A and B ′ is 50 to 100 mol% based on all the monomer units, and most preferably the monomer unit A,
  • Component (a) of the present invention contains another water-soluble polymer that does not contain polymer A, as long as it does not significantly inhibit the bactericidal and antifouling properties of the germicidal and antifouling detergent for hard surfaces of the present invention. You may.
  • the component (a) of the present invention has a weight average molecular weight of 1,000 to 6,000,000, preferably 10,000 to 6,000,000, particularly preferably 100,000 to 6,000,000, The weight average molecular weight was obtained by gel permeation chromatography using polyethylene glycol as a standard substance, using a mixed solvent of acetate nitrile and water (phosphate buffer) as a developing solvent.
  • the component (a) is preferably present in the germicidal and antifouling detergent of the present invention in an amount of 0.01 to 30% by weight.
  • the concentration of the component (a) is 0.01 to 10% by weight, more preferably 0.02 to 5% by weight.
  • the concentration of the component (a) in the tank is preferably from 0.1 to 10 ppm.
  • the component (b) of the present invention is a fungicidal compound having at least one quaternary ammonium group having a molecular weight of less than 1000, preferably 500 or less.
  • the bactericidal compound referred to in the present invention refers to a compound having a property that the number of mouths measured by the following method is 10 or less.
  • Escherichia coli IF ⁇ 3972
  • Staphylococcus aureus Staphylococcus aureus: IFQ12732
  • IF03972 and IF012732 have been deposited at the Institute for Fermentation, Osaka, located at 17-85, Jusanhoncho, Yodogawa-ku, Osaka, Japan and can be sold.
  • Prepare a 1% by weight aqueous solution of the test compound [component (b)] add 50 ⁇ l of 10 8 to 10 9 bacterial suspensions to 2 ml of the aqueous solution, mix well, and allow to stand for 5 minutes.
  • bactericidal compound having a molecular weight of less than 1000 as the component (b) compounds represented by the following formulas (1) to (3) are preferable, and among them, water-soluble compounds are particularly preferable.
  • water-soluble means that the amount dissolved in 1 L of water at 20 is 1 g or more.
  • R 1 and R s are each independently an alkyl group or alkenyl group having 6 to 18 carbon atoms, preferably 8 to 16 carbon atoms, preferably an alkyl group
  • R 3 and R 4 are each independently It is an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms.
  • X is an aromatic ring or an ester group or an amide group selected from —COO—, one CONH—, one OC ⁇ -one, and one NHCO—
  • R 2 is a hydroxyl group when X is an ester group or an amide group.
  • An alkylene group having 1 to 6 carbon atoms which may be substituted, and when X.
  • R 11 is an ethylene group or a propylene group, preferably an ethylene group, and k is an average number of 1 to 10, preferably an average number of 1 to 5.
  • R 5 is an alkylene group having 1 to 3 carbon atoms.
  • R 7 to R 1! Is one or more, preferably one or two of them, an alkyl group having 8 to 18, preferably 8 to 14, more preferably 8 to 12 carbon atoms, and the remaining Is an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms.
  • M is a number of 0 or 1.
  • Y— is an anion, particularly preferably a halogen ion, a sulfate ion, an alkyl sulfate ion having 1 to 3 carbon atoms, or an aromatic sulfonate ion which may be substituted with an alkyl group having 1 to 3 carbon atoms.
  • More preferred component (b) is a compound of the above general formula (1) or (3), most preferably a compound of the following general formula.
  • R represents an alkyl group having 8 to 6 carbon atoms.
  • R represents an optionally branched alkyl group having 6 to 12 carbon atoms
  • m represents a number of 1 to 5 on average.
  • two Rs represent an alkyl group having 8 to 12 carbon atoms which may be different.
  • the component (b) is preferably 0.001 to 30% by weight in the disinfectant and antifouling detergent of the present invention. Specifically, the hard surface of the object is washed by a spraying device such as a trigger or an aerosol, or by a method such as application. In the case of cleaning, the concentration of the component (b) is 0.001 to 5% by weight, more preferably 0.005 to 2% by weight. On the other hand, in the cleaning method using water in the toilet tank, When it is used in a toilet cleaner that can administer an appropriate amount of cleaning liquid to the water in the tank by providing a device in the water supply path, it is contained in an amount of 0.1 to 30% by weight, more preferably 1 to 20% by weight. You. The concentration of the component (b) in the tank is preferably 0.01 to: LOp pm.
  • the component (a) / component (b) is preferably 3'0Zl to 1Z50 in weight ratio, and 20/1 to 1/20 in order to obtain a bactericidal effect while maintaining sufficient antifouling properties. More preferably, 10/1 to 1/10 is most preferable.
  • the germicidal antifouling detergent for hard surfaces of the present invention further contains (c) a surfactant other than the component (b) [hereinafter referred to as the component (c)].
  • a surfactant other than the component (b) hereinafter referred to as the component (c).
  • Nonionic surfactants, amphoteric surfactants It is preferable to add one or more surfactants selected from surfactants and anionic surfactants.
  • nonionic surfactant examples include compounds represented by the following formulas (c1) to (c3).
  • R ′′ 11 is a primary linear alkyl group, a branched alkyl group or a secondary alkyl group having an average carbon number of 10 to 20, preferably 10 to 18.
  • EO is ethylene oxide and n Is 5 to 20 as an average number of added moles.
  • R c2 is a primary alkyl group having an average carbon number of 10 to 20, preferably 10 to 18; EO indicates ethylene oxide, and PO indicates propylene oxide. k and 1 are the average number of added models, p is 5 to 15, and q is 1 to 5. EO and PO may be added randomly, or PO may be added after adding EO, or vice versa. Further, the block additional body may be three or more blocks. ]
  • R e3 is a linear or branched alkyl or alkenyl group having 8 to 18 carbon atoms or an alkylphenyl group having an alkyl group having 8 to 18 carbon atoms, is an alkylene group having 2 to 4 carbon atoms
  • G is a residue derived from a reducing sugar having 5 or 6 carbon atoms, preferably a glucose residue
  • X is a number having an average value of 0 to 6
  • y is a number having an average value of 1 to 10.
  • amphoteric surfactant examples include an aminoxide represented by the following general formula (c4) and a betaine represented by the following general formula (c5).
  • R c 5 is an alkyl or alkenyl group having 8 to 18 carbon atoms
  • R c6 is an alkylene group having 5 to several atoms
  • R c7 and R c8 are each independently an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group.
  • A is a group selected from one COO—, one CONH—, one C—one, —NH CO—, —0—, and r is a number of 0 or 1.
  • R c5 , R c6 , R c7 , R′K A and r are the same as those described in the general formula (c 4).
  • R c9 is an alkylene group which ⁇ 1 carbon atoms which may be 5 substituted by a hydroxyl group, T is ten S 0 3 -, - CO_ ⁇ -, an anionic group selected from a S Of. r is a number of 0 or 1. ].
  • anionic surfactant examples include alkylbenzene sulfonates having 8 to 18 carbon atoms in the alkyl group, alkane sulfonates, ⁇ '-olefin sulfonates, alkyl sulfates, polyoxyethylene alkyl ether sulfates, and the like. Polyoxyethylene alkyl ether acetate And the like.
  • blending one or more of the surfactants selected from the above formulas (c3), (c4) and (c5) provides excellent detergency without impairing the antifouling effect. It is preferable for obtaining.
  • the amount of the surfactant is preferably 0.01% by weight or more and less than 50% by weight, more preferably less than 50% by weight, in order to obtain sufficient detergency and foaming power without impairing the disinfecting and antifouling effects. Is 0.1% by weight or more, particularly preferably 0.1 to 30% by weight.
  • the anionic surfactant (hereinafter referred to as (cA)] should be blended in an amount that has no effect in order to reduce the bactericidal and antifouling properties.
  • (cA) ) / (b) must be present in a proportion by weight not exceeding 1.0, preferably not exceeding 0.75. Beyond this range, both antifouling and disinfecting effects cannot be obtained.
  • the component (c) is preferably 0.1 to 30% by weight in the germicidal and antifouling detergent of the present invention.
  • the target hard surface is directly cleaned by a spraying device such as a trigger or an aerosol, or by a method such as application.
  • the concentration of the component (j) is 0.1 to 20% by weight, more preferably 0.2 to 10% by weight.
  • the content is 0.5 to 30% by weight, more preferably 1 to 30% by weight. .
  • the concentration of the component (c) in the toilet tank is preferably 0.1 to 20 ppm.
  • a water-soluble solvent [hereinafter referred to as “component (d)”] is preferably blended as an optional component for the purpose of improving detergency against organic stains.
  • component (d) a water-soluble solvent
  • a polyhydric alcohol having 4 to 12 carbon atoms [3] a compound represented by the following general formula (dl), [4] a compound represented by the following general formula (d2), and [5]
  • One or more compounds selected from the compounds represented by the following general formula (d3) are preferable.
  • R dl and R d2 each independently represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a phenyl group or a benzyl group, and both R dl l and R d2 are hydrogen atoms Except in cases. s and t each independently represent a number from 0 to 10, except when both s and t are 0.
  • R d3 and R d4 represent an alkyl group having 1 to 3 carbon atoms.
  • R d5 represents an alkyl group having 1 to 3 carbon atoms. Show.
  • Examples of the monohydric alcohol having 2 to 5 carbon atoms in [1] generally include ethanol, propyl alcohol, and isopropyl alcohol. By incorporating these lower alcohols, the stability of the system at low temperatures can be further improved.
  • polyhydric alcohol having 4 to 12 carbon atoms of [2] examples include isoprene glycol, 2,2,4-trimethyl-1,3-pentanediol, 1,5-pentanediol, 1,8-octanediol, In addition to 9-nonanediol, ethylene glycol, propylene glycol, diethylene glycol, dipropylene glycol, and glycerin, monoalkyl glyceryl ethers having an alkyl group having 3 to 8 carbon atoms and the like are included.
  • the number of carbon atoms is particularly preferably 1 to 4.
  • s and t which are the average addition mole numbers of ethylene oxide (hereinafter, referred to as EO) and propylene oxide (hereinafter, referred to as PO), are 0 to 10, respectively.
  • the order of addition is not particularly limited, and may be randomly added.
  • glycol phenyl ether are preferred from the viewpoints of detergency and usability.
  • 1,3-dimethyl-2-imidazolidinone and 1,3-dimethyl-2-imidazolidinone are exemplified as preferable ones, and as the compound of [5], 3- (3-dimethyl-2-imidazolidinone) is used. Preference is given to methoxy-3-methylbutanol, 3-ethoxy-3-methylbutanol and the like.
  • a water-soluble solvent selected from the compounds of [1], [2] and [3] is preferable from the viewpoint of damage to the base material, and in particular, ethanol, isopropyl alcohol, ethylenedaricol, propylene glycol, diethylene glycol, dipropylene Glycol, daliserine, isoplendaricol, propylene glycol monomethyl ether, propylene dalicol monoethyl ether, propylene glycol monopropyl ether, propylene glycol monobutyl ether, and monoalkyl glyceryl ether having 3 to 8 carbon atoms in the alkyl group
  • a water-soluble solvent selected from the compounds of [1], [2] and [3] is preferable from the viewpoint of damage to the base material, and in particular, ethanol, isopropyl alcohol, ethylenedaricol, propylene glycol, diethylene glycol, dipropylene Glycol, daliserine, isoplendaricol, propylene glycol
  • the component (d) is preferably 0.1 to 50% by weight in the germicidal antifouling detergent of the present invention. In such cases, the concentration of component (d) is 0.! 20% by weight, more preferably 0.5% to 10% by weight.
  • an appropriate amount of water in the tank is provided by installing a device in the tank or an arbitrary water supply path. When it is used for an auto cleaner for a toilet which can administer a suitable washing liquid, it is contained in an amount of 1 to 50% by weight, more preferably 5 to 30% by weight.
  • the concentration of the component (d) in the toilet tank is preferably 0.01 to 20 ppm.
  • a chelating agent for the purpose of dissolving the inorganic dirt, and improving the detergency and the sterilizing effect, (e) It is preferable to add a chelating agent as a component.
  • the chelating agent include (1) tripolyphosphoric acid, pyrophosphoric acid, orthophosphoric acid, hexametaphosphoric acid and alkali metal salts thereof, (2) ethylenediaminetetraacetic acid, hydroxyiminodiacetic acid, dihydroxyethyldalicin, nitrilotriacetic acid, Hydroxyethylene diamine triacetic acid, diethylene triamine pentaacetic acid, triethylene tetramine hexaacetic acid and their metal salts or alkaline earth metal salts, (3) aminotrimethylene phosphonic acid, 1-hydroxyethylidene 1,1-diphosphonic acid, ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, N-oxide of aminotrimethylenephospho
  • the component (e) is preferably 0.1 to 20% by weight in the germicidal antifouling detergent of the present invention. More specifically, the hard surface of the object is sprayed with a trigger or aerosol, or by a method such as coating.
  • the concentration of the component (e) is 0.1 to 10% by weight, more preferably 0.3 to 7% by weight.
  • the washing method using water in the toilet tank 1-20% by weight, more preferably 2-20% by weight when used in toilet auto cleaners that can supply an appropriate amount of cleaning liquid to the water in the tank by installing a device inside or in an optional water supply path It is contained.
  • the concentration of the component (e) in the toilet tank is preferably 0.01 to 20 ppm.
  • the present invention may use a pH adjuster when adjusting pH.
  • pH adjusters include inorganic acids such as hydrochloric acid and sulfuric acid, acid agents such as citric acid, co-octanoic acid, malic acid, fumaric acid, tartaric acid, malonic acid, and maleic acid; sodium hydroxide; Alkaline agents such as sodium carbonate and potassium carbonate, such as potassium hydroxide, ammonia and derivatives thereof, and amine salts such as monoethanolamine diethanolamine and triethanolamine, may be used alone or in combination. Further, these acid agents and alkali agents may be used in combination as a buffer system. .
  • the hard surface sterilizing and antifouling detergent of the present invention is preferably adjusted by the above-mentioned pH adjuster so that ⁇ 1 in 20 becomes 2 to 12 and particularly pH 3 to 1 It is preferable to set it to 1 from the viewpoint of the antifouling effect.
  • one or more water-soluble polymers can be added for the purpose of imparting adhesion during use and improving ease of use.
  • the water-soluble polymer is not particularly limited, but may be one selected from water-soluble polymers described in JP-A-8-209194, page 6, column 10 to page 7, column 11. The above is preferred.
  • the hard surface sterilizing and antifouling detergent of the present invention contains additives, such as fragrances, antibacterial agents, and viscosity modifiers, which are blended with ordinary detergents within a range that does not impair the effects of the present invention.
  • additives such as fragrances, antibacterial agents, and viscosity modifiers, which are blended with ordinary detergents within a range that does not impair the effects of the present invention.
  • Agents, pigments, dyes, suspending agents and the like can be added.
  • at least one selected from foaming aids such as toluene sulfonic acid, xylene sulfonic acid, cumene sulfonic acid, arkeel succinic acid, and metal salts of these metals is added. I can do it.
  • any one of the optional agents may be used in combination with the optional component.
  • One or more powders or tablets may be used in the form of one or more powders which can be immediately dissolved in a solvent such as water or provided with sustained release by combining optional components.
  • any one of the component (a) and the component (b) or the optional component may be used in a liquid state, and the other may be used in a solid state such as a powder.
  • the form of the sterilizing and antifouling detergent of the present invention at the time of use is not particularly limited, but is preferably a liquid composition containing component (a), component (b) and optional components, with the balance being water.
  • a solid or gel composition may be formed using a coagulant such as polyethylene glycol, polyethylene glycol fatty acid ester, polyethylene glycol fatty acid diester, fatty acid, or salt.
  • the content of water is preferably 10 to 98% by weight, more preferably 20 to 95% by weight in the case of a liquid composition or a gel composition. In the case of a solid composition, it is preferably at most 30%, more preferably at most 20%.
  • a germicidal antifouling detergent having the composition shown in Table 1 was prepared, and its antifouling property and bactericidal property were evaluated by the following methods. Table 1 shows the results.
  • Stain removal is 80% or more
  • Stain removal is 60% or more and less than 80%
  • Stain removal is 40% or more and less than 60%
  • Stain removal is 20% or more and less than 40%
  • Stain removal is less than 20%.
  • Escherichia coli IFO 3972
  • Staphylococcus aureus Staphylococcus cauruseus: IFO 12732
  • the bactericidal test was conducted by adding 50 ⁇ l of 10 8 to 10 3 bacterial suspensions to 2 ml of the germicidal antifouling agent shown in Table 1 and mixing well. Was. After standing, the mixture 0.1 ml is collected and added to 0.9 ml of LP diluent and mixed well to reduce the effect of the washing solution on the bacteria, then this mixture is spread on S CDLP agar medium, and the E. coli is 37t: Incubate for 24 hours at 37 ° C for 48 hours. Count the number of grown colonies after culture. In the sterilization test, the same sterilizing and antifouling agent was tested in five test plots for each standing time, and the sterilizing property was evaluated according to the following scores.
  • 'Polymer B Mercoat 550 [diallyldimethylammonium chloride and acrylamide (mole ratio 30/70) copolymer (Ca1gon, weight average molecular weight 5,000,000, measured by gel permeation chromatogram, Polyethylene glycol is used as standard)]
  • 'Polymer A Mercoat 100 [Homopolymer of diaryldimethylammonium chloride (Ca1gon, weight average molecular weight 400,000, measured by gel permeation chromatogram) Use polyethylene glycol as standard)]
  • Fungicidal compound A Sanizole C [cocoalkyl dimethyl benzylammonium chloride (manufactured by Kao Corporation)]
  • -Bactericidal compound B Koyinmin D 10 P [didecyldimethylammonium chloride (manufactured by Kao Corporation)]
  • Fungicidal compound C Benzetonium chloride [Wako reagent, cationic compound with the following structure]
  • Alkyl darcoside (a mixture of straight chain alkyl groups with 12 and 14 carbon atoms, average saccharide condensation degree 1.2 [mixture of condensation degrees 1 and 2])
  • ES Polyoxyethylene lauryl ether sulfate with an average number of moles of added EO of 2.2 moles
  • Betaine N-lauroylaminopropyl-N, N-dimethyl-N-potoxymethylammonium betaine
  • ED TA-4 Na Ethylenediaminetetraacetic acid tetrasodium salt
  • pH adjuster hydrochloric acid and / or sodium hydroxide (all used in aqueous solution)
  • the toilet auto-cleaner composition shown in Table 2 was prepared and poured into a toilet tank with a spot so that the value in Kazuko (ppm) was obtained.
  • the antifouling property when flushing was evaluated by the following method did.
  • Table 2 shows the results.
  • a commercially available toilet bowl (C730B, manufactured by Tohoku Kikai Co., Ltd.) was used to evaluate the difficulty of getting dirty. That is, the toilet was washed with the composition, and the hardiness of the toilet when allowed to stand for one week was visually measured based on the following criteria.
  • Table 2 of well sales added a suspension 0. 05Ml and SCD medium 0. lml of Staphylococcus aureus which had been adjusted to 10 4 cfu / ral to adjust the composition 2 ml concentration in Katsuko, 3 7. After standing at C for 18 hours, the bacteriostatic activity value was determined by the following formula.
  • Bacteriostatic activity value log (number of viable cells after blank culture)-log (number of viable cells after culture of evaluation sample) ⁇ evaluation>
  • Fungicidal compound D 0.1 0.3 0.5 1 1 0.5 1 1 2

Abstract

A bactericidal antifouling detergent for hard surfaces which comprises (a) a polymer which has a weight-average molecular weight of 1,000 to 6,000,000 and in which monomer units having at least one group selected among quaternary ammonium groups and tertiary amino groups account for 10 to 100 mol% of all the monomer units, (b) a bactericidal compound having a molecular weight lower than 1,000 and having a quaternary ammonium group, and (c) a surfactant, and in which when the surfactant comprises an anionic surfactant (cA), the proportion of (cA) to (b) by weight does not exceed 1.0. The bactericidal antifouling detergent sterilizes hard surfaces and shows antifouling properties, i.e., prevents fouling substances from adhering thereto and enables fouling substances adherent thereto to be easily removed. When used in a whole house, especially when applied to the walls and floors of the kitchen, bathroom, toilet, washstand, etc. and to instruments and apparatuses placed therein, the detergent enables sterilization, prevention of fouling substance adhesion, and easy cleaning.

Description

明細書 硬質表面用殺菌防汚洗浄剤 発明の属する技術分野  Description Sterilizing and antifouling detergent for hard surfaces Technical field to which the invention pertains
本発明は、 硬質表面の殺菌、 及び防汚性、 すなわち汚れの付着の防止、 及び付着した汚 れを容易に除去することを可能にする硬質表面用の洗浄剤組成物に関し、 住居内全般、 特 に台所や浴室、 トイレ、 洗面台などの、 壁や床、 器具、 機器などに使用した際に、 殺菌並 びに汚れの付着防止及び易洗浄を可能にする硬質表面用殺菌防汚洗浄剤に関する。 従来の技術  The present invention relates to a cleaning composition for hard surfaces that can disinfect hard surfaces and prevent soiling, that is, prevent adhesion of dirt, and easily remove attached dirt. In particular, when used on walls, floors, utensils, equipment, etc. in kitchens, bathrooms, toilets, washbasins, etc. . Conventional technology
生活場面では様々な場所で汚れが発生する。 それらの汚れを除去するために各種の洗浄 剤が開発され、 その洗浄力を強化すべく検討がなされてきた。 これら努力により、 頑固な 汚れを落とすための手段が多く提案されている。  Dirt occurs in various places in daily life. Various cleaning agents have been developed to remove such dirt, and studies have been made to enhance their cleaning power. With these efforts, many measures have been proposed to remove stubborn dirt.
また、 このように汚れの除去性に優れた洗浄剤を開発する一方で、 汚れを付きにくくす る技術及び処理を施すことで付いた汚れを落とし易くする技術 (以後防汚性とする) に関 する技術も多く検討されており、 洗浄剤として応用する技術が見出されている。 例えば、 特開平 2— 1 4 5 6 9 7号公報には、 特定構造のスルホベタイン型両性界面活性剤を配合 する水洗トイレ用清浄剤が、 特開平 3— 3 5 0 9 7号公報には、 スルホコハク酸ジエステ ルを含有する軟便付着防止性に優れ洗浄効果の高い水性トイレ用清浄剤が、 特開平 1 0— 1 6 9 7号公報には、 特定の界面活性剤と水溶性溶剤を特定比率で配合する洗浄剤が記載 されている。 特に、 特開平 9一 1 6 9 9 9 5号公報には、 処理後の硬質表面に対する水の 接触角が 3 0度以下となるような洗浄剤が優れた防汚性を示し、 具体的に、 防汚基剤とし て、 ァニオン界面活性剤と分子中に 4級アンモニゥム基を含む界面活性剤又は水溶性ポリ マーとの組み合わせが挙げられている。  In addition, while developing a cleaning agent that is excellent in the removal of dirt, a technology that makes it difficult to remove dirt and a technology that makes it easy to remove dirt attached to it (hereinafter referred to as antifouling properties) Many related technologies are also being studied, and technologies applied as cleaning agents have been found. For example, Japanese Unexamined Patent Publication No. 2-1456977 discloses a flush toilet detergent containing a sulfobetaine-type amphoteric surfactant having a specific structure, and Japanese Unexamined Patent Publication No. 3-35097. Japanese Patent Laid-Open Publication No. Hei 10-16797 discloses a water-based toilet cleaner containing a sulfosuccinic acid ester, which is excellent in loose stool adhesion and has a high cleaning effect. Detergents to be mixed in proportions are described. In particular, Japanese Unexamined Patent Application Publication No. Hei 9-16995 describes that a cleaning agent having a water contact angle of 30 degrees or less with a hard surface after treatment shows excellent antifouling property. As an antifouling base, a combination of an anionic surfactant with a surfactant containing a quaternary ammonium group in a molecule or a water-soluble polymer is mentioned.
以上のように、 従来から防汚性に関する技術は多く検討されてきている。 し力しながら、 従来の技術は、 水垢や便等の付着による汚れの発生を中心に抑制するものであり、 微生物 ゃカビ由来の黒ずみに関する汚れについては不十分である。 加えて最近では、 生活環境の 改善にともなって、 目に見える汚れに加えて、 衛生面での問題を懸念する人が増えてきて おり、 殺菌に対する要求も高まってきている。  As described above, many antifouling technologies have been studied. However, the conventional technology mainly suppresses the generation of stains due to adhesion of water scales and stool, etc., and is insufficient for stains related to darkening caused by microorganisms and mold. In addition, recently, with the improvement of living environment, more and more people are concerned about hygiene problems in addition to visible dirt, and the demand for sterilization is increasing.
このような殺菌に関する考え方として殺菌剤の配合が 案される。 しかしながら、 家庭 用に使用することが一般的である殺菌剤を前記洗浄剤に配合した場合、 防汚性と殺菌性の 両方の効果を相殺してしまい、 満足できる殺菌性及び防汚性を達成することは極めて困難 であった。  As a concept regarding such disinfection, the formulation of a disinfectant is proposed. However, when a bactericide, which is generally used for home use, is added to the above-mentioned cleaning agent, the effects of both the antifouling property and the bactericidal property are offset, and satisfactory bactericidal properties and antifouling properties are achieved. It was extremely difficult to do so.
本発明の課題は、 家庭で使用でき、 .トイレ、 浴室、 台所まわりなどの硬質表面の洗浄に おいて、 優れた洗浄力のみならず殺菌性と防汚性の両方を満足できる水準で付与できる剤 を提供することにある。 本発明の開示  An object of the present invention is to provide home use, and in cleaning hard surfaces such as toilets, bathrooms, and kitchen surroundings, not only excellent detergency but also sterilization and antifouling properties can be imparted at a satisfactory level. Agent. Disclosure of the present invention
本発明は、 (a ) 重量平均分子量が 1, 0 0 0〜6, 0 0 0, 0 0 0であって、 4級アン モニゥム基及び 3級ァミノ基より選ばれた少なくとも 1ケの基を有するモノマー単位をそ の比率が全モノマ一単位に対して.1 0〜1 0 0モル%含む重合体、 ( b ) 分子量が 1 , 0 0 0未満であって、 4級アンモニゥム基を有する殺菌性化合物、 及び (c ) 界面活性剤を含 有し、 界面活性剤として (c A) 陰イオン界面活性剤を含有する場合、 (c A) / (b ) が 重量比率で、 1. 0を越えない硬質表面用殺菌防汚洗浄剤である。 The present invention relates to (a) a compound having a weight-average molecular weight of 1,000 to 6,000, and at least one group selected from a quaternary ammonium group and a tertiary amino group; A polymer having a monomer unit content of 0.1 to 100 mol% with respect to one monomer unit; (b) a sterilizer having a molecular weight of less than 1,000 and having a quaternary ammonium group (CA) / (b) when the surfactant contains (cA) anionic surfactant, and (cA) a surfactant. It is a germicidal and antifouling detergent for hard surfaces not exceeding 1.0 by weight.
(a) 成分を 0. 01~30重量%、 (b) 成分を 0. 001~30重量%、 及び ( c ) 成分を 0. 01〜50重量%含有することが好ましい。  It is preferable to contain 0.01 to 30% by weight of the component (a), 0.001 to 30% by weight of the component (b), and 0.01 to 50% by weight of the component (c).
本発明は、 上記組成物を硬質表面に適用することにより硬質表面を洗浄、 殺菌しそして 硬質表面への汚れの付着を防止する方法と上記組成物を硬質表面を洗浄、 殺菌しそして硬 質表面への汚れの付着を防止する用途を提供する。 発明の詳細な説明  The present invention relates to a method for cleaning and disinfecting a hard surface by applying the above composition to a hard surface and for preventing the adhesion of dirt to the hard surface. Provide use for preventing the adhesion of dirt to the surface. Detailed description of the invention
本発明の (a) 成分は、 4級アンモニゥム基及び/又は 3級アミノ基を有するモノマー 単位 (以下、 モノマー単位 Aとする) を 10~100モル%含有す ¾重合体である。  The component (a) of the present invention is a polymer containing 10 to 100 mol% of a monomer unit having a quaternary ammonium group and / or a tertiary amino group (hereinafter, referred to as a monomer unit A).
モノマ一単位 Aは、 4級アンモニゥム基(複数であってもよい) を含有するモノマ一 (以 下、 モノマー Aとする) を重合するか又は 3級ァミノ基 (複数であってもよい) を含有す るモノマー (以下、 モノマー A' とする) を重合して得られるモノマー単位であってもよ く、 3級アミノ基を 4級化して 4級アンモニゥム化したものであってもよい。  Monomer unit A is obtained by polymerizing a monomer (hereinafter, referred to as monomer A) containing a quaternary ammonium group (or a plurality of monomers) or a tertiary amino group (or a plurality of monomers). The monomer unit may be a monomer unit obtained by polymerizing a contained monomer (hereinafter, referred to as monomer A ′), or may be a quaternary ammonium obtained by quaternizing a tertiary amino group.
4級アンモニゥム基を有するモノマー Aの好ましい例として、 即ち、 モノマー単位 Aが 由来する例として、 下記式 (4) の化合物を挙げることができる。  As a preferred example of the monomer A having a quaternary ammonium group, that is, as an example from which the monomer unit A is derived, a compound represented by the following formula (4) can be mentioned.
R12R13Q二 C(FS4 )— X\ R15 、 γ-R12R13Q2 C (FS4) — X \ R15, γ-
R>6 R17 式中、 R12、 R13、 R "は、 それぞれ独立して、 水素原子、 水酸基又は炭素数 1〜3のァ ルキル基である。 Xは炭素数 1〜12のアルキレン基、 — COOR18—、 — CONHR18—、 — OCOR18—、 一 R19—〇CO— R18—から選ばれる基である。 ここで R18、 R19は、 それ ぞれ独立して、 炭素数 1~5のアルキレン基である。 R 15は炭素数 1〜3のアルキル基もし くはヒドロキシアルキル基又は R12R13C = C (R14)— X—である。 R16は炭素数 1〜3のァ ルキル基、 ヒドロキシアルキル基、 ベンジル基であり、 R17はヒドロキシ基、 力ルポキシル 基、 スルホン酸基もしくは硫酸エステル基で置換されていてもよい炭素数 1~10のアル キル基又はべンジル基であり、 R17がアルキル基、 ヒドロキシアルキル基又はべンジル基の 場合は、 Y—は陰イオンを示す。 R> in 6 R 17 formula, R 12, R 13, R " are each independently hydrogen atom, a hydroxyl group or a § alkyl group having 1 to 3 carbon atoms. X represents an alkylene group having 1 to 12 carbon atoms , —COOR 18 —, — CONHR 18 —, — OCOR 18 —, — R 19 —〇CO—R 18 — where R 18 and R 19 are each independently carbon An alkylene group having a number of 1 to 5. R 15 is an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms or R 12 R 13 C = C (R 14 ) —X— R 16 has a carbon number R 17 is an alkyl group having 1 to 3 alkyl groups, hydroxyalkyl group, or benzyl group; and R 17 is an alkyl group having 1 to 10 carbon atoms which may be substituted with a hydroxy group, a carbonyl group, a sulfonic acid group or a sulfate group. Or, when R 17 is an alkyl group, a hydroxyalkyl group or a benzyl group, Y— represents an anion.
また、 R17がカルボキシル基、 スルホン酸基、 硫酸エステル基を含む場合、 Y—は存在せ ず、 R17中のこれらの基は陰イオンとなる。 Y—の陰イオンとしては、 ハロゲンイオン、 硫 酸イオン、 炭素数 1~ 3のアルキル硫酸エステルイオン、 炭素数 1〜 3のアルキル基で置 換されていてもよい芳香族スルホン酸イオン、 ヒドロキシイオンを挙げることができる。 これらの中でもァクリロイル (又はメ夕クリロイル) アミノアルキル (炭素数 1〜5) -N, N, N—トリアルキル (炭素数 1~3) 4級アンモニゥム塩、 ァクリロイル (又は メ夕クリロイル) 才キシアルキル (炭素数 1〜5) -N, N, N—トリアルキル (炭素数 1-3) 4級アンモニゥム塩、 N— (ω—アルケニル (炭素数 3〜: L 0)) — Ν, Ν, Ν- トリアルキル (炭素数 1〜3) 4級アンモニゥム塩、 Ν, Ν—ジ (ω—アルケニル (炭素 数 3〜10)) — Ν, Ν—ジアルキル (炭素数 1〜3) 4級アンモニゥム塩が好ましく、 特 にジァリルジメチルアンモニゥム埠が良好である。 When R 17 contains a carboxyl group, a sulfonic acid group, or a sulfate group, Y— does not exist, and these groups in R 17 become anions. Examples of the anion of Y— include a halogen ion, a sulfate ion, an alkyl sulfate ion having 1 to 3 carbon atoms, an aromatic sulfonate ion optionally substituted by an alkyl group having 1 to 3 carbon atoms, and a hydroxy ion. Can be mentioned. Among them, acryloyl (or methacryloyl) aminoalkyl (1 to 5 carbon atoms) -N, N, N-trialkyl (1 to 3 carbon atoms) quaternary ammonium salt, acryloyl (or methacryloyl) 1-5 carbon atoms) -N, N, N-trialkyl (1-3 carbon atoms) quaternary ammonium salt, N— (ω-alkenyl (3-3 carbon atoms: L 0)) — Ν, Ν, Ν- Trialkyl (1 to 3 carbon atoms) quaternary ammonium salt, Ν, —-di (ω-alkenyl (3 to 10 carbon atoms)) — ジ, Ν-dialkyl (1 to 3 carbon atoms) quaternary ammonium salt is preferred Especially, the diaryl dimethyl ammonium pier is good.
3級ァミノ基のモノマー A' の好ましい例として、 即ち、 モノマ一単位 Α 'が由来する 化合物として、 下記式 (5) の化合物を挙げることができる (5) Preferred examples of the tertiary amino group monomer A ′, that is, a compound derived from a monomer unit Α ′, include a compound represented by the following formula (5). (Five)
R 2R13C:R 2 R 13 C:
Figure imgf000004_0001
式中、 Rl2、 Rl3、 Rl R15及び R16は、 前記記載と同じである。
Figure imgf000004_0001
Wherein, R l2, R l3, R l R 15 and R 16 are the same as above described.
これらの中でも N, N—ジアルキル (炭素数 1~3) アミノアルキル (炭素数 1~5) ァクリレート (又はメタクリレート)、 N, N—ジアルキル (炭素数 1〜3) アミノアルキ ル (炭素数 1~5) アクリルアミド、 N, N—ジ (ω—アルケニル (炭素数 3〜: L 0)) - Ν—メチルァミンが好ましく、 ジァリルメチルァミンが特に好ましい。  Among them, N, N-dialkyl (C1-3) aminoalkyl (C1-5) acrylate (or methacrylate), N, N-dialkyl (C1-3) aminoalkyl (C1-5) ) Acrylamide, N, N-di (ω-alkenyl (C 3 -L 0))-Ν-methylamine is preferred, and diarylmethylamine is particularly preferred.
モノマー A' を 4級化する場合は、 4級化剤としてメチルクロリド、 メチルプロミド、 ベンジルクロリド、 ジメチル硫酸、 ジェチル硫酸、 モノクロ口酢酸又はその塩、 クロルス ルホン酸又はその塩、 3—クロ口— 2—ヒドロキシプロパンスルホン酸又はその塩、 ェチ レンォキシド、 プロピレンォキシド、 グリシジルェ一テルを用いて行うことが好ましい。 尚、 エチレンォキシド、 プロピレンォキシド、 グリシジルェ一テルを使用する場合は、 予 め硫酸、 塩酸、 炭素数 1~12のカルボン酸、 ァリルスルホン酸などでモノマー単位を中 和した後反応させることが好ましい。  When quaternizing monomer A ', quaternizing agents such as methyl chloride, methyl bromide, benzyl chloride, dimethyl sulfate, getyl sulfate, monochloroacetic acid or a salt thereof, chlorsulfuric acid or a salt thereof, and 3-chloro-2 -It is preferably carried out using hydroxypropanesulfonic acid or a salt thereof, ethylene oxide, propylene oxide, or glycidyl ether. When ethylene oxide, propylene oxide, or glycidyl ether is used, it is preferable to react after neutralizing the monomer units with sulfuric acid, hydrochloric acid, a carboxylic acid having 1 to 12 carbon atoms, or arylsulfonic acid in advance. .
本発明の (a) 成分は、 モノマー単位 A (複数種であってもよい) からなる重合体のみ ならず、 モノマ一単位 A (複数種であってもよい) と他のモノマー単位 (以下、 モノマー 単位 Bとする) とか 6構成された重合体であってもよい。 (モノマ一 A' を使用する場合は、 ァミン型のモノマー単位を有していてもよい。) この場合、 モノマ一単位 Aとモノマー単位 B (複数種であってもよい) との配列様式は、 ブロック、 交互、 周期、 統計 (ランダムを 含む)、 グラフト型の何れであってもよい。  The component (a) of the present invention includes not only a polymer composed of monomer units A (a plurality of types may be used), but also a monomer unit A (a plurality of types may be used) and another monomer unit (hereinafter, referred to as “a”). Or a polymer composed of 6 units. (When monomer A 'is used, it may have an amine type monomer unit.) In this case, the arrangement of monomer unit A and monomer unit B (there may be plural types) , Block, alternating, periodic, statistical (including random), or graft type.
モノマー単位 Aとモノマー単位 Bとから構成される重合体は、 例えば、 それぞれの前駆 体モノマ一を共重合することによって得ることができる。 この場合、 モノマ一単位 Bとし ては、 下記のモノマー群 (i ) ~ (V) から選ばれるモノマー由来のモノマー単位が好ま しく、 (i ) ~ (iii) 又は (V) 記載のモノマー由来のモノマ一単位がより好ましく、 特 に防汚効果の点から ( i)、 (ii) 又は (V) のモノマー由来のモノマー単位が最も好まし い。  The polymer composed of the monomer units A and B can be obtained, for example, by copolymerizing the respective precursor monomers. In this case, the monomer unit B is preferably a monomer unit derived from a monomer selected from the following monomer groups (i) to (V), and is preferably a monomer unit derived from the monomers described in (i) to (iii) or (V). A monomer unit is more preferred, and a monomer unit derived from the monomer (i), (ii) or (V) is most preferred, particularly from the viewpoint of antifouling effect.
( i) アクリル酸又はその塩、 メ夕クリル酸又はその塩、 マレイン酸又はその塩、 無水マ レイン酸、 スチレンスルホン酸塩、 スルホプロピルメタクリレート、 2—アクリルアミド - 2—メチルプロパンスルホン酸またはその塩、 リン酸モノ一 ω—メタクリロイルォキシ アルキル (炭素数 1〜12) から選ばれる陰イオン基含有化合物  (i) Acrylic acid or a salt thereof, methacrylic acid or a salt thereof, maleic acid or a salt thereof, maleic anhydride, styrenesulfonate, sulfopropyl methacrylate, 2-acrylamide-2-methylpropanesulfonic acid or a salt thereof Anion group-containing compounds selected from mono-ω-methacryloyloxyalkyl phosphates (1 to 12 carbon atoms)
(ii) アクリル (又はメタクリル) アミド、 N, N—ジメチルァミノプロピルアクリル酸 (又はメタクリル酸) アミド、 N, N—ジメチルアクリル (又はメタクリル) アミド、 N 一ビニル一2—力プロラクタム、 N—ビニルー 2—ピロリ ドンから選ばれるアミド基含有 化合物  (ii) Acrylic (or methacrylic) amide, N, N-dimethylaminopropylacrylic acid (or methacrylic acid) amide, N, N-dimethylacrylic (or methacrylic) amide, N-vinyl-1-2-prolactam, N -Amide-containing compounds selected from vinyl-2-pyrrolidone
(iii) アクリル酸 (又はメ夕クリル酸) アルキル (炭素数 1〜5)、 アクリル酸 (又はメ タクリル酸) 2—ヒドロキシェチル、 アクリル酸 (又はメ夕クリル酸) 一 N, N—ジメチ ルァミノアルキル (炭素数 1〜5)、 酢酸ビニルから選ばれるエステル基含有化合物 (iii) Alkyl acrylate (or methacrylic acid) alkyl (1-5 carbon atoms), acrylic acid (or methacrylic acid) 2-hydroxyethyl, acrylic acid (or methacrylic acid) 1 N, N-dimethyl Ester group-containing compounds selected from luminoalkyl (C1-5) and vinyl acetate
(iv) エチレン、 プロピレン、 N—プチレン、 イソプチレン、 N—ペンテン、 イソプレン、 2—メチル— 1ーブテン、 N—へキセン、 2—メチル一 1—ペンテン、 3—メチルー 1一 ペンテン、 4ーメチルー 1一ペンテン、 2—ェチル一 1—ブテン、 スチレン、 ビニルトル ェン、 α—メチルスチレン、 ァリルアミン、 Ν, Ν—ジァリルァミン、 Ν, Ν—ジァリル 一 Ν—アルキル (炭素数 1~5) ァミン、 エチレンォキシド、 プロピレンォキシド、 2— ビニルピリジン、 4 -ビニルピリジンから選ばれる化合物 (iv) Ethylene, propylene, N-butylene, isobutylene, N-pentene, isoprene, 2-methyl-1-butene, N-hexene, 2-methyl-1-pentene, 3-methyl-1-pentene, 4-methyl-11 Penten, 2-ethyl 1-butene, styrene, vinyl tol Benzene, α-methylstyrene, arylamine, Ν, Ν-diallylamine, Ν, Ν-diaryl-l-alkyl (1-5 carbon atoms) amine, ethyleneoxide, propyleneoxide, 2-vinylpyridine, 4-vinyl Compound selected from pyridine
(V) 二酸化硫黄。  (V) Sulfur dioxide.
モノマー単位 Αとモノマー単位 Βを有する重合体は前記のような共重合による合成方法 の他、 モノマー単位 Aを含む重合体に前記 (i) ~ ( のモノマ一、 特に好ましくは前記 The polymer having the monomer unit Α and the monomer unit は may be synthesized by the above-mentioned copolymerization method, or may be formed into a polymer containing the monomer unit A by one of the monomers (i) to (
(i)、 (ii) のモノマーをグラフト重合して得てもよいし、 前記 (i) ~ (v) のモノマー を含む重合体に前記一般式 (4) のモノマ一をグラフト重合して得てもよいし、 前記 (i) 〜 (V) のモノマーを含む重合体、 特に好ましくは前記 (i)、 (ii) のモノマーを含む重合 体に前記一般式 (5) のモノマ一をグラフト重合した後、 これを 4級化してもよい。 It may be obtained by graft polymerization of the monomers of (i) and (ii), or may be obtained by graft polymerization of the monomer of the general formula (4) to a polymer containing the monomers of (i) to (v). Or a polymer containing the monomers (i) to (V), particularly preferably a polymer containing the monomers (i) and (ii), graft-polymerized with the monomer of the general formula (5). After that, it may be quaternized.
本発明のモノマー単位 Bで最も好ましいものは、 カルボン酸基、 スルホン酸基から選ば れる 1つ以上の基を有する [但し 4級アンモニゥム基を有さない] モノマー、 すなわち前 記 (i) のモノマー由来のモノマー単位 (以下モノマー単位 B' とする) である。  The most preferred monomer unit B of the present invention is a monomer having one or more groups selected from a carboxylic acid group and a sulfonic acid group (but not having a quaternary ammonium group), ie, the monomer of the above (i) Monomer unit (hereinafter referred to as monomer unit B ').
本発明の (a) 成分を構成する重合体はいかなる重合法によって得てもよいが、 ラジカ ル重合法が特に好ましく、 塊状、 溶液、 又は乳化系にてこれを行うことができる。 ラジカ ル重合は加熱によりこれを開始してもよいが、 開始剤として、 2, 2 ' ーァゾビス (2— アミジノプロパン) 二塩酸塩、 2, 2' —ァゾビス (N, N—ジメチレンイソブチルアミ ジン) 二塩酸塩、 などのァゾ系開始剤、 過酸化水素及び、 過酸化べンゾィル、 t一ブチル ヒドロパーォキシド、 クメンヒドロパ一ォキシド、 メチルェチルケトンパ一ォキシド、 過 安息香酸などの有機過酸化物、 過硫酸ナトリウム、 過硫酸カリウム、 過硫酸アンモニゥム などの過硫酸塩、 過酸化水素一 Fe3+などのレドックス開始剤、 など既存のラジカル開始剤 を用いてもよいし、 光増感剤の存在ノ又は非存在下での光照射や、 放射線照射により重合 を開始させてもよい。 Although the polymer constituting the component (a) of the present invention may be obtained by any polymerization method, a radical polymerization method is particularly preferable, and the polymerization can be carried out in a bulk, solution, or emulsion system. Radical polymerization may be initiated by heating, but the initiators are 2,2'-azobis (2-amidinopropane) dihydrochloride and 2,2'-azobis (N, N-dimethyleneisobutylamidine). Azo initiators such as dihydrochloride, and organic peroxides such as hydrogen peroxide and benzoyl peroxide, t-butyl hydroperoxide, cumene hydroperoxide, methylethylketone peroxide, perbenzoic acid, etc. Existing radical initiators such as oxides, persulfates such as sodium persulfate, potassium persulfate, ammonium persulfate, etc., redox initiators such as hydrogen peroxide-Fe 3+ , etc. may be used, and photosensitizers may be used. Polymerization may be started by light irradiation or radiation irradiation in the presence or absence of a compound.
本発明の (a) 成分は、 モノマー単位 Aの単一重合体並びにモノマー単位 A及びモノマ —単位 Bのコポリマーから選ばれる重合体の複数種の混合物であつてもよい。  The component (a) of the present invention may be a homopolymer of the monomer unit A or a mixture of plural kinds of polymers selected from a copolymer of the monomer unit A and the monomer-unit B.
本発明の (a) 成分における、 より好ましい構成は、 モノマー単位 Aとモノマー単位 B' の合計が全モノマー単位に対して 50〜100モル%のものであり、 最も好ましくはモノ マ一単位 A、 B' のモル比が、 モノマー単位 A/ [モノマ一単位 A +モノマー単位 B' ] = 0. 3— 0. 99のものであり、 特には 0. 4~0. 99ものである。  A more preferred constitution in the component (a) of the present invention is that the total of the monomer units A and B ′ is 50 to 100 mol% based on all the monomer units, and most preferably the monomer unit A, The molar ratio of B ′ is such that monomer unit A / [monomer unit A + monomer unit B ′] = 0.3-0.99, particularly 0.4-0.99.
本発明の (a) 成分は本発明の硬質表面用殺菌防汚洗浄剤の殺菌性、 防汚性を著しく阻 害しない限りにおいて、 重合体 Aを含有しない他の水溶性重合体を含有していてもよい。 本発明の (a) 成分は重量平均分子量が 1, 000〜6, 000, 000、 好ましくは 10, 000~6 , 000, 000、 特に好ましくは 100, 000~6, 000, 00 0であり、 この重量平均分子量はァセ卜二トリルと水の混合溶媒 (リン酸緩衝液) を展開 溶媒とし、 ゲルパ一ミエーシヨンクロマトグラフィ一でポリエチレングリコ一ルを標準物 質として求めたものである。  Component (a) of the present invention contains another water-soluble polymer that does not contain polymer A, as long as it does not significantly inhibit the bactericidal and antifouling properties of the germicidal and antifouling detergent for hard surfaces of the present invention. You may. The component (a) of the present invention has a weight average molecular weight of 1,000 to 6,000,000, preferably 10,000 to 6,000,000, particularly preferably 100,000 to 6,000,000, The weight average molecular weight was obtained by gel permeation chromatography using polyethylene glycol as a standard substance, using a mixed solvent of acetate nitrile and water (phosphate buffer) as a developing solvent.
(a) 成分は本発明の殺菌防汚洗浄剤中に好ましくは 0. 01〜30重量%でぁり、 詳 しくはトリガ一やエアゾールなどの噴霧装置や、 塗布するような方法にて対象の硬質表面 を洗浄するような場合は、 (a) 成分の濃度は 0.01〜10重量%、 より好ましくは 0.02〜5 重量%であり、 一方、 トイレタンク内の水を利用した洗浄方法において、 タンク内または 任意の給水経路に装置を設けることで夕ンク内の水に適量な洗浄液を投与することができ るトイレ用オートクリーナーに用.いる場合は、 1~30重量%、 より好ましくは 2~20重量% 含有される。 なおタンク内の (a) 成分の濃度は 0. l〜10p pmが好ましい。 本発明の (b) 成分は、 分子量が 1000未満、 好ましくは 500以下の少なくとも 1 つの 4級アンモニゥム基を有する殺菌性化合物である。 本発明でいう殺菌性化合物とは、 下記方法により測定されるコ口二一数が 10以下の性質を示す化合物のことをいう。 The component (a) is preferably present in the germicidal and antifouling detergent of the present invention in an amount of 0.01 to 30% by weight. In the case of cleaning a hard surface, the concentration of the component (a) is 0.01 to 10% by weight, more preferably 0.02 to 5% by weight. On the other hand, in the cleaning method using water in the toilet tank, Or use it as an auto cleaner for toilets that can apply an appropriate amount of cleaning liquid to the water in the evening water by installing a device in an optional water supply channel.If it is used, use 1 to 30% by weight, more preferably 2 to 20% by weight. % By weight. The concentration of the component (a) in the tank is preferably from 0.1 to 10 ppm. The component (b) of the present invention is a fungicidal compound having at least one quaternary ammonium group having a molecular weight of less than 1000, preferably 500 or less. The bactericidal compound referred to in the present invention refers to a compound having a property that the number of mouths measured by the following method is 10 or less.
ぐ殺菌性化合物測定方法 >  Germicidal compound measurement method>
供試菌として大腸菌 (Es che r i ch i a c o l l : I F〇 3972 ) と黄色ブド ゥ球菌(S t aphy l oc oc cu s aur eus : I FQ12732)を用いる。 I F03972と I F012732は日本国大阪市淀川区十三本町二町目 17番 85号在の 財団法人発酵研究所 Institute for Fermentation, Osaka に寄託され、 分譲できる。 試験化合物 〔(b) 成分〕 の 1重量%水溶液を調製し、 該水溶液 2ml中に 108〜109 個の細菌浮遊液 50 μ 1を加えよく混合した後、 5分間放置する。 放置後、 この混合液を 0. 1ml採取して 0. 9m 1の LP希釈液中に加えて十分混合し、 前記化合物の菌への 影響を低下させ、 次いでこの混合液を S CD LP寒天培地上に塗布し、 大腸菌は 37でで 24時間、 黄色ブドウ球菌は 37 で 48時間培養する。 培養後の生育したコロニー数を 数える。 なお殺菌試験は同じ化合物についてそれぞれ同時に 5回ずつ行う (5回 X3)。 こ の実験結果において、 大腸菌及び黄色プドウ球菌の両方のコロニー数が 10以下となるも のを殺菌性ありとする。 なお、 前記規定以外の実験条件の詳細は、 防菌防黴ハンドブックAs test bacteria, Escherichia coli (IF と 3972) and Staphylococcus aureus (Staphylococcus aureus: IFQ12732) are used. IF03972 and IF012732 have been deposited at the Institute for Fermentation, Osaka, located at 17-85, Jusanhoncho, Yodogawa-ku, Osaka, Japan and can be sold. Prepare a 1% by weight aqueous solution of the test compound [component (b)], add 50 μl of 10 8 to 10 9 bacterial suspensions to 2 ml of the aqueous solution, mix well, and allow to stand for 5 minutes. After standing, 0.1 ml of this mixture was taken, added to 0.9 ml of LP diluent, and mixed well to reduce the effect of the compound on the bacteria. Culture on E. coli at 37 for 24 hours and Staphylococcus aureus at 37 for 48 hours. Count the number of grown colonies after culture. Perform the sterilization test for the same compound 5 times each (5 times X3). In the results of this experiment, those with less than 10 colonies of both E. coli and Staphylococcus aureus are considered bactericidal. For details of experimental conditions other than the above, see the Handbook
(日本防菌防黴学会編、 技報堂出版) の p 686に記載されている浮遊試験法 (定量的検 査法) に従う。 In accordance with the floating test method (quantitative test method) described in p. 686 of the Japan Society of Antibacterial and Fungicide, edited by Gihodo.
(b) 成分となる分子量 1000未満の殺菌性化合物としては、 下記式 (1) 〜 (3) で示される化合物が好ましく、 それらのうち特に水溶性のものが好ましい。 ここで水溶性 とは 20での水 1 Lに溶解する量が 1 g以上であることを指す。  As the bactericidal compound having a molecular weight of less than 1000 as the component (b), compounds represented by the following formulas (1) to (3) are preferable, and among them, water-soluble compounds are particularly preferable. Here, "water-soluble" means that the amount dissolved in 1 L of water at 20 is 1 g or more.
Figure imgf000006_0001
Figure imgf000006_0001
Figure imgf000006_0002
Figure imgf000006_0002
FT FT
(3)  (3)
γ- γ-
10 Ten
R8 R R 8 R
式中、 R1及び Rsは、 それぞれ独立して炭素数 6〜18、 好ましくは 8〜16のアルキル 基又はアルケニル基、 好ましくはアルキル基であり、 R3及び R4は、 それぞれ独立して炭素 数 1〜3のアルキル基又はヒドロキシアルキル基である。 Xは芳香環又は— COO—、 一 CONH—、 一 OC〇一、 一NHCO—から選ばれるエステル基あるいはアミド基であり、 R2は、 Xがエステル基又はアミド基である場合には水酸基で置換されていてもよい炭素数 1~6のアルキレン基であり、 X.が芳香環の場合には、 水酸基で置換されていてもよい炭 素数 1〜 6のアルキレン基又は一(0— RU) k—である。 ここで R11はエチレン基又はプロピ レン基、 好ましくはエチレン基であり、 kは平均 1〜10、 好ましくは平均 1~5の数で ある。 R5は炭素数 1〜3のアルキレン基である。 R7~R1!)はこれらの内 1つ以上、 好まし くは 1つ又は 2つが炭素数 8〜18、 好ましくは 8〜14、 より好ましくは 8〜12のァ ルキル基であり、 残りが炭素数 1~3のアルキル基又はヒドロキシアルキル基である。 ま た、 mは 0又は 1の数である。 さらに Y—は、 陰イオンであり、 特にハロゲンイオン、 硫酸 イオン、 炭素数 1〜 3のアルキル硫酸イオン、 炭素数 1~3のアルキル基で置換されてい てもよい芳香族スルホン酸イオンが好ましい。 In the formula, R 1 and R s are each independently an alkyl group or alkenyl group having 6 to 18 carbon atoms, preferably 8 to 16 carbon atoms, preferably an alkyl group, and R 3 and R 4 are each independently It is an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms. X is an aromatic ring or an ester group or an amide group selected from —COO—, one CONH—, one OC〇-one, and one NHCO—, and R 2 is a hydroxyl group when X is an ester group or an amide group. An alkylene group having 1 to 6 carbon atoms which may be substituted, and when X. is an aromatic ring, an alkylene group having 1 to 6 carbon atoms which may be substituted with a hydroxyl group or one (0-RU) k — Here, R 11 is an ethylene group or a propylene group, preferably an ethylene group, and k is an average number of 1 to 10, preferably an average number of 1 to 5. is there. R 5 is an alkylene group having 1 to 3 carbon atoms. R 7 to R 1!) Is one or more, preferably one or two of them, an alkyl group having 8 to 18, preferably 8 to 14, more preferably 8 to 12 carbon atoms, and the remaining Is an alkyl group or a hydroxyalkyl group having 1 to 3 carbon atoms. M is a number of 0 or 1. Further, Y— is an anion, particularly preferably a halogen ion, a sulfate ion, an alkyl sulfate ion having 1 to 3 carbon atoms, or an aromatic sulfonate ion which may be substituted with an alkyl group having 1 to 3 carbon atoms.
より好ましい (b) 成分は上記一般式 (1) 又は (3) の化合物であり、 最も好ましく は下記の一般式の化合物である。  More preferred component (b) is a compound of the above general formula (1) or (3), most preferably a compound of the following general formula.
Figure imgf000007_0001
式中、 Rは炭素数 8〜: L 6のアルキル基を示す。
Figure imgf000007_0001
In the formula, R represents an alkyl group having 8 to 6 carbon atoms.
Figure imgf000007_0002
式中、 Rは分岐していてもよい炭素数 6〜12のアルキル基、 mは平均 1~5の数を示 す。
Figure imgf000007_0003
式中、 2つの Rは異なっていてもよい炭素数 8〜12のアルキル基を示す。
Figure imgf000007_0002
In the formula, R represents an optionally branched alkyl group having 6 to 12 carbon atoms, and m represents a number of 1 to 5 on average.
Figure imgf000007_0003
In the formula, two Rs represent an alkyl group having 8 to 12 carbon atoms which may be different.
(b) 成分は本発明の殺菌防汚洗浄剤中に好ましくは 0. 001~30重量%、 詳しく はトリガ一やエアゾールなどの噴霧装置や、 塗布するような方法にて対象の硬質表面を洗 浄するような場合は、 ( b )成分の濃度は 0.001〜5重量%、より好ましくは 0.005〜2重量% であり、 一方、 トイレタンク内の水を利用した洗浄方法において、 タンク内または任意の 給水経路に装置を設けることでタンク内の水に適量な洗浄液を投与することができるトイ レ用ォ一トクリーナーに用いる場合は、 0.1〜30重量%、 より好ましくは 1〜20重量%含有 される。 なおタンク内の (b) 成分の濃度は 0.01〜: LOp pmが好ましい。 The component (b) is preferably 0.001 to 30% by weight in the disinfectant and antifouling detergent of the present invention. Specifically, the hard surface of the object is washed by a spraying device such as a trigger or an aerosol, or by a method such as application. In the case of cleaning, the concentration of the component (b) is 0.001 to 5% by weight, more preferably 0.005 to 2% by weight. On the other hand, in the cleaning method using water in the toilet tank, When it is used in a toilet cleaner that can administer an appropriate amount of cleaning liquid to the water in the tank by providing a device in the water supply path, it is contained in an amount of 0.1 to 30% by weight, more preferably 1 to 20% by weight. You. The concentration of the component (b) in the tank is preferably 0.01 to: LOp pm.
本発明において、 充分な防汚性を保った上で、 殺菌効果を得るために (a) 成分/ (b) 成分は重量比で 3'0Zl〜lZ50が好ましく、 20/1〜1/20がより好ましく、 10/1〜 1/10が最も好ましい。  In the present invention, the component (a) / component (b) is preferably 3'0Zl to 1Z50 in weight ratio, and 20/1 to 1/20 in order to obtain a bactericidal effect while maintaining sufficient antifouling properties. More preferably, 10/1 to 1/10 is most preferable.
本発明の硬質表面用殺菌防汚洗浄剤は、 更に (c) として (b) 成分以外の 面活性剤 〔以下、 (c) 成分という〕 を含有する。 界面活性剤としては、 非イオン界面活性剤、 両性 界面活性剤、 陰イオン界面活性剤から選ばれる 1種以上の界面活性剤を添加することが好 ましい。 The germicidal antifouling detergent for hard surfaces of the present invention further contains (c) a surfactant other than the component (b) [hereinafter referred to as the component (c)]. Nonionic surfactants, amphoteric surfactants It is preferable to add one or more surfactants selected from surfactants and anionic surfactants.
非イオン界面活性剤としては、 下記式 (c 1) 〜式 (c 3) の化合物が挙げられる。 Rcl-0(EO)nH (c 1) Examples of the nonionic surfactant include compounds represented by the following formulas (c1) to (c3). R cl -0 (EO) n H (c 1)
〔式中、 R"11は平均炭素数 10~20、 好ましくは 10〜18の一級の直鎖アルキル基、 分 岐鎖アルキル基又は二級のアルキル基である。 EOはエチレンオキサイドであり、 nは平 均付加モル数として 5 ~ 20である。〕 [Wherein, R ″ 11 is a primary linear alkyl group, a branched alkyl group or a secondary alkyl group having an average carbon number of 10 to 20, preferably 10 to 18. EO is ethylene oxide and n Is 5 to 20 as an average number of added moles.]
Rc2-0(EO)p/(PO)qH (c 2) R c2 -0 (EO) p / (PO) q H (c 2)
〔式中、 Rc2は平均炭素数 1 0~20、 好ましくは 10~1 8の一級のアルキル基である。 EOはエチレンオキサイド、 POはプロピレンオキサイドを示す。 k及び 1は平均付加モ ル数であり、 pは 5〜 1 5、 qは 1〜5である。 EOと P Oはランダム付加又は EOを付 加した後、 POを付加してもよく、 またその逆のようなブロック付加体でもよい。 また、 ブロック付加体は 3つ以上のブロックであってもよい。〕 [In the formula, R c2 is a primary alkyl group having an average carbon number of 10 to 20, preferably 10 to 18; EO indicates ethylene oxide, and PO indicates propylene oxide. k and 1 are the average number of added models, p is 5 to 15, and q is 1 to 5. EO and PO may be added randomly, or PO may be added after adding EO, or vice versa. Further, the block additional body may be three or more blocks. ]
Rc3—(〇Rc4)xGy (c 3) R c3 — (〇R c4 ) x G y (c 3)
〔式中、 Re3は直鎖又は分岐鎖の炭素数 8〜18のアルキル基もしくはアルケニル基又は炭 素数 8〜18のアルキル基を有するアルキルフエニル基、 は炭素数 2〜4のアルキレン 基、 Gは炭素数 5又は 6の還元糖に由来する残基好ましくはグルコース残基であり、 Xは 平均値 0 ~ 6の数、 yは平均値 1〜 1 0の数を示す。〕。 Wherein R e3 is a linear or branched alkyl or alkenyl group having 8 to 18 carbon atoms or an alkylphenyl group having an alkyl group having 8 to 18 carbon atoms, is an alkylene group having 2 to 4 carbon atoms, G is a residue derived from a reducing sugar having 5 or 6 carbon atoms, preferably a glucose residue, X is a number having an average value of 0 to 6, and y is a number having an average value of 1 to 10. ].
両性界面活性剤としては下記一般式 (c 4) で表されるアミンォキシド及び一般式 (c 5) で表されるベタインを挙げることができる。  Examples of the amphoteric surfactant include an aminoxide represented by the following general formula (c4) and a betaine represented by the following general formula (c5).
Figure imgf000008_0001
式中、 Rc 5は炭素数 8〜18のアルキル基又はアルケニル基であり、 Rc6は炭素数 1〜 5のアルキレン基である。 Rc 7、 Rc 8は、 それぞれ独立して、 炭素数 1〜3のアルキル基 又はヒドロキシアルキル基である。 Aは一 COO—、 一 CONH—、 一〇C〇一、 -NH CO—、 —0—から選ばれる基であり、 rは 0又は 1の数である。
Figure imgf000008_0001
Wherein, R c 5 is an alkyl or alkenyl group having 8 to 18 carbon atoms, R c6 is an alkylene group having 5 to several atoms. R c7 and R c8 are each independently an alkyl group having 1 to 3 carbon atoms or a hydroxyalkyl group. A is a group selected from one COO—, one CONH—, one C—one, —NH CO—, —0—, and r is a number of 0 or 1.
(c 5)
Figure imgf000008_0002
式中、 Rc5、 Rc6、 Rc7, R'K A及び rは前記一般式 (c 4) 記載のものと同じである。 Rc9は水酸基で置換されていてもよい炭素数 1 ~ 5のアルキレン基であり、 Tは一〇 S 03-、 — CO〇—、 一 S Ofから選ばれる陰イオン基である。 rは 0又は 1の数である。〕。
(c 5)
Figure imgf000008_0002
In the formula, R c5 , R c6 , R c7 , R′K A and r are the same as those described in the general formula (c 4). R c9 is an alkylene group which ~ 1 carbon atoms which may be 5 substituted by a hydroxyl group, T is ten S 0 3 -, - CO_〇-, an anionic group selected from a S Of. r is a number of 0 or 1. ].
陰イオン界面活性剤としてはアルキル基の炭素数 8 ~1 8のアルキルベンゼンスルホン 酸塩、 アルカンスルホン酸塩、 α'ォレフインスルホン酸塩、 アルキル硫酸エステル塩、 ポ リオキシエチレンアルキルエーテル硫酸塩、 ポリオキシエチレンアルキルエーテル酢酸塩 等を挙げることができる。 Examples of the anionic surfactant include alkylbenzene sulfonates having 8 to 18 carbon atoms in the alkyl group, alkane sulfonates, α'-olefin sulfonates, alkyl sulfates, polyoxyethylene alkyl ether sulfates, and the like. Polyoxyethylene alkyl ether acetate And the like.
本発明では特に前記式 (c 3)、 (c 4) 及び (c 5) 力 ^ら選ばれる界面活性剤の一種以 上を配合することが、 防汚効果を損なうことなく優れた洗浄性を得る上で好ましい。 (c) 成分の界面活性剤の配合量は、 殺菌及び防汚効果を損なうことなく十分な洗浄力や起泡力 を得るために好ましくは 0. 01重量%以上、 50重量%未満、 より好ましくは 0. 1重 量%以上であり、 特に好ましくは 0. 1~30重量%である。  In the present invention, in particular, blending one or more of the surfactants selected from the above formulas (c3), (c4) and (c5) provides excellent detergency without impairing the antifouling effect. It is preferable for obtaining. (C) The amount of the surfactant is preferably 0.01% by weight or more and less than 50% by weight, more preferably less than 50% by weight, in order to obtain sufficient detergency and foaming power without impairing the disinfecting and antifouling effects. Is 0.1% by weight or more, particularly preferably 0.1 to 30% by weight.
但し、 陰イオン界面活性剤 [以下 (cA) とする] は、 殺菌性及び防汚性を低下させる ため、 影響のない量で配合されるべきであり、 (cA) を含有する場合、 (cA) / (b) が重量比率で、 1. 0越えない量、 好ましくは 0. 75を越えない量で配合しなければな らない。 この範囲を越えると、 防汚及び殺菌効果の両方を得ることはできない。  However, the anionic surfactant [hereinafter referred to as (cA)] should be blended in an amount that has no effect in order to reduce the bactericidal and antifouling properties. When (cA) is contained, (cA) ) / (b) must be present in a proportion by weight not exceeding 1.0, preferably not exceeding 0.75. Beyond this range, both antifouling and disinfecting effects cannot be obtained.
(c) 成分は本発明の殺菌防汚洗浄剤中に好ましくは 0.1~30重量%であり、 詳しくは トリガーやエアゾールなどの噴霧装置や、 塗布するような方法にて対象の硬質表面を直接 洗浄するような場合は、 (じ)成分の濃度は0.1〜20重量%、より好ましくは 0.2〜10重量% であり、 一方、 トイレタンク内の水を利用した洗浄方法において、 タンク内または任意の 給水経路に装置を設けることでタンク内の水に適量な洗浄液を投与することができるトイ レ用ォ一トクリーナーに用いる場合は、 0.5〜30重量%、 より好ましくは 1〜30重量%含有 される。 なおトイレのタンク内の (c) 成分の濃度は 0. l〜20p pmが好ましい。 本発明では、 任意成分の成分として、 有機汚れに対する洗浄力向上の目的で水溶性溶剤 [以下 (d) 成分とする] を配合することが好ましく、 [1] 炭素数 1〜5の 1価アルコー ル、 [2] 炭素数 4~12の多価アルコール、 [3] 下記の一般式 (d l) で表される化合 物、 [4] 下記の一般式 (d2) で表される化合物及び [5] 下記の一般式 (d3) で表さ れる化合物から選ばれる一種以上が好ましい。  The component (c) is preferably 0.1 to 30% by weight in the germicidal and antifouling detergent of the present invention. Specifically, the target hard surface is directly cleaned by a spraying device such as a trigger or an aerosol, or by a method such as application. In such a case, the concentration of the component (j) is 0.1 to 20% by weight, more preferably 0.2 to 10% by weight. On the other hand, in the cleaning method using water in the toilet tank, the water in the tank or any water supply When used in toilet cleaners that can administer an appropriate amount of washing liquid to the water in the tank by providing a device in the route, the content is 0.5 to 30% by weight, more preferably 1 to 30% by weight. . The concentration of the component (c) in the toilet tank is preferably 0.1 to 20 ppm. In the present invention, a water-soluble solvent [hereinafter referred to as “component (d)”] is preferably blended as an optional component for the purpose of improving detergency against organic stains. [1] A monovalent alcohol having 1 to 5 carbon atoms [2] a polyhydric alcohol having 4 to 12 carbon atoms, [3] a compound represented by the following general formula (dl), [4] a compound represented by the following general formula (d2), and [5] One or more compounds selected from the compounds represented by the following general formula (d3) are preferable.
RdlO(C2 OHC3 0) Rd2 (D D R dl O (C 2 OHC 30 ) R d , 2 (D D
Figure imgf000009_0001
Figure imgf000009_0001
Rd5OC(CH3)2C¾C¾OH (d 3) R d5 OC (CH 3 ) 2 C¾C¾OH (d 3)
式中、 Rdl及び Rd2は、 それぞれ独立して、 水素原子、 炭素数 1〜8のアルキル基、 フエ ニル基又はベンジル基を示すが、 Rdll及び Rd2の双方が水素原子となる場合を除く。 s及 び tは、 それぞれ独立して、 0~10の数を示すが、 s及び tの双方が 0である場合を除 く。 Rd3及び Rd4は炭素数 1〜3のアルキル基を示す。 Rd5は炭素数 1〜 3のアルキル基を 示す。 In the formula, R dl and R d2 each independently represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, a phenyl group or a benzyl group, and both R dl l and R d2 are hydrogen atoms Except in cases. s and t each independently represent a number from 0 to 10, except when both s and t are 0. R d3 and R d4 represent an alkyl group having 1 to 3 carbon atoms. R d5 represents an alkyl group having 1 to 3 carbon atoms. Show.
[1] の炭素数 2~ 5の 1価アルコールとしては、 一般的にエタノール、 プロピルアル コール、 イソプロピルアルコールが挙げられる。 これらの低級アルコールを配合すること により低温における系の安定性を更に向上させることができる。  Examples of the monohydric alcohol having 2 to 5 carbon atoms in [1] generally include ethanol, propyl alcohol, and isopropyl alcohol. By incorporating these lower alcohols, the stability of the system at low temperatures can be further improved.
[2] の炭素数 4~ 12の多価アルコールとしては、 イソプレングリコール、 2, 2, 4—トリメチルー 1, 3—ペンタンジオール、 1, 5—ペン夕ンジオール、 1, 8ーォク 夕ンジオール、 1, 9ーノナンジオール、 エチレングリコ一ル、 プロピレングリコ一ル、 ジエチレングリコール、 ジプロピレングリコール、 グリセリンの他、 アルキル基の炭素数 が 3〜 8のモノアルキルグリセリルエーテル等が挙げられる。  Examples of the polyhydric alcohol having 4 to 12 carbon atoms of [2] include isoprene glycol, 2,2,4-trimethyl-1,3-pentanediol, 1,5-pentanediol, 1,8-octanediol, In addition to 9-nonanediol, ethylene glycol, propylene glycol, diethylene glycol, dipropylene glycol, and glycerin, monoalkyl glyceryl ethers having an alkyl group having 3 to 8 carbon atoms and the like are included.
[3] の化合物は、 一般式 (dl) において、 Rdl、 Rd2がアルキル基である場合の炭素 数は 1〜4が特に好ましい。 また、 一般式 (d l) 中、 エチレンオキサイド (以下、 EO という) 及びプロピレンオキサイド (以下、 POという) の平均付加モル数の s及び tは、 それぞれ 0~10の数であるが、 EOと POの付加順序は特に限定されず、 ランダム付加 したものであってもよい。 [3] の化合物の具体例としては、 エチレングリコ一ルモノプチ ルェ一テル、 ジプロピレングリコ一ルジメチルエーテル、 ジエチレングリコールモノェチ ルエーテル、 ジエチレングリコールモノブチルエーテル、 プロピレングリコールモノメチ ルエーテル、 プロピレングリコールモノプロピルエーテル、 プロピレングリコ一ルモノブ チルエーテル、 プロピレングリコールモノェチルェ一テル、 プロピレングリコ一ルジメチ ルェ一テル、 ポリオキシエチレン (平均付加モル数 =2〜 3) ポリオキシプロピレン (平 均付加モル数 = 2〜 3 ) グリコールジメチルェ一テル、 ポリオキシエチレン (平均付加モ ル数 = 1〜4) グリコ一ルフエ二ルェ一テル、 フエ二ルカルビトール、 フエ二ルセ口ソル ブ、 ベンジルカルビトール等が挙げられる。 このうち、 洗浄力及び使用感の点から、 プロ ピレンダリコールモノメチルエーテル、 ジエチレングリコールモノブチルエーテル、 ポリ ォキシエチレン (平均付加モル数 = 1〜4) グリコールフエニルエーテルが好ましい。 また、 [4] の化合物としては、 1, 3—ジメチルー 2—イミダゾリジノン、 1, 3—ジ ェチル—2—イミダゾリジノンが好適なものとして例示され、 [5] の化合物としては 3— メ卜キシー 3—メチルブ夕ノール、 3—エトキシー 3—メチルブ夕ノール等が好ましい。 これらのなかでも基材に対する損傷性の点から [1]、 [2] 及び [3] の化合物から選 ばれる水溶性溶剤が好ましく、 特にエタノール、 イソプロピルアルコール、 エチレンダリ コール、 プロピレングリコール、 ジエチレングリコール、 ジプロピレングリコール、 ダリ セリン、 イソプレンダリコール、 プロピレングリコールモノメチルエーテル、 プロピレン ダリコールモノェチルエーテル、 プロピレングリコールモノプロピルエーテル、 プロピレ ングリコ一ルモノブチルエーテル及びアルキル基の炭素数が 3〜 8のモノアルキルグリセ リルェ一テルから選ばれる水溶性溶剤が好ましい。 In the compound of [3], in the general formula (dl), when R dl and R d2 are an alkyl group, the number of carbon atoms is particularly preferably 1 to 4. In the general formula (dl), s and t, which are the average addition mole numbers of ethylene oxide (hereinafter, referred to as EO) and propylene oxide (hereinafter, referred to as PO), are 0 to 10, respectively. The order of addition is not particularly limited, and may be randomly added. Specific examples of the compound of [3] include ethylene glycol monobutyl ether, dipropylene glycol dimethyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, propylene glycol monomethyl ether, propylene glycol monopropyl ether, propylene glycol Monobutyl ether, propylene glycol monoethyl ether, propylene glycol dimethyl ether, polyoxyethylene (average number of moles = 2-3) polyoxypropylene (average number of moles = 2-3) glycol dimethyl Ether, polyoxyethylene (average number of added moles = 1 to 4) Glycol phenyl ether, phenyl carbitol, phenyl sorbitol, benzyl carbitol and the like. Among these, propylene glycol monomethyl ether, diethylene glycol monobutyl ether, and polyoxyethylene (average number of moles = 1 to 4) glycol phenyl ether are preferred from the viewpoints of detergency and usability. Further, as the compound of [4], 1,3-dimethyl-2-imidazolidinone and 1,3-dimethyl-2-imidazolidinone are exemplified as preferable ones, and as the compound of [5], 3- (3-dimethyl-2-imidazolidinone) is used. Preference is given to methoxy-3-methylbutanol, 3-ethoxy-3-methylbutanol and the like. Among these, a water-soluble solvent selected from the compounds of [1], [2] and [3] is preferable from the viewpoint of damage to the base material, and in particular, ethanol, isopropyl alcohol, ethylenedaricol, propylene glycol, diethylene glycol, dipropylene Glycol, daliserine, isoplendaricol, propylene glycol monomethyl ether, propylene dalicol monoethyl ether, propylene glycol monopropyl ether, propylene glycol monobutyl ether, and monoalkyl glyceryl ether having 3 to 8 carbon atoms in the alkyl group And a water-soluble solvent selected from
(d) 成分は本発明の殺菌防汚洗浄剤中に好ましくは 0.1〜50重量%であり、 詳しくは トリガ一やエアゾールなどの噴霧装置や、 塗布するような方法にて対象の硬質表面を洗浄 するような場合は、 (d) 成分の濃度は 0.!〜 20重量%、 より好ましくは 0.5〜10重量%で あり、 一方、 トイレタンク内の水を利用した洗浄方法において、 タンク内または任意の給 水経路に装置を設けることでタンク内の水に適量な洗浄液を投与することができるトイレ 用オートクリーナーに用いる場合は、 1〜50重量%、 より好ましくは 5〜30重量%含有され る。 なおトイレのタンク内の (d) 成分の濃度は 0.01~20p pmが好ましい。 本発明では無機汚れを溶解し、 洗浄力及び殺菌効果を向上させる目的で、 さらに (e) 成分として、 キレート剤を配合することが好ましい。 キレート剤としては (1 ) トリポリ リン酸、 ピロリン酸、 オルソリン酸、 へキサメタリン酸及びこれらのアルカリ金属塩、 (2 ) エチレンジァミン四酢酸、 ヒドロキシィミノ二酢酸、 ジヒドロキシェチルダリシン、 ニト リロ三酢酸、 ヒドロキシエチレンジァミン三酢酸、 ジエチレントリアミン五酢酸、 トリェ チレンテトラミン六酢酸及びこれらのアル力リ金属塩もしくはアル力リ土類金属塩、 ( 3 ) アミノトリメチレンホスホン酸、 1ーヒドロキシェチリデン一 1 , 1ージホスホン酸、 ェ チレンジアミンテトラメチレンホスホン酸、 ジエチレントリアミンペンタメチレンホスホ ン酸、 ァミノトリメチレンホスホン酸の N—ォキサイド及びこれらのアルカリ金属塩もし くはアルカリ土類金属塩、 (4 ) アクリル酸及びメタクリル酸から選ばれるモノマーの単一 重合体又は共重合体、 アクリル酸—マレイン酸共重合体、 ポリ α—ヒドロキアクリル酸及 びそのアルカリ金属塩、 (5 ) クェン酸、 コハク酸、 リンゴ酸、 フマル酸、 酒石酸、 マロン 酸、 マレイン酸から選ばれる多価カルボン酸及びそれらのアルカリ金属塩から選ばれる 1 種以上、 (6 ) アルキルグリシン一 Ν, Ν—ジ酢酸、 ァスパラギン酸— Ν, Ν—ジ酢酸、 セ リン一 Ν, Ν—ジ酢酸、 グルタミン酸二酢酸、 エチレンジアミンジコハク酸又はこれらの 塩が好ましく、 特に (2 )、 (3 )、 ( 5 ) の化合物が好ましい。 The component (d) is preferably 0.1 to 50% by weight in the germicidal antifouling detergent of the present invention. In such cases, the concentration of component (d) is 0.! 20% by weight, more preferably 0.5% to 10% by weight. On the other hand, in a cleaning method using water in the toilet tank, an appropriate amount of water in the tank is provided by installing a device in the tank or an arbitrary water supply path. When it is used for an auto cleaner for a toilet which can administer a suitable washing liquid, it is contained in an amount of 1 to 50% by weight, more preferably 5 to 30% by weight. The concentration of the component (d) in the toilet tank is preferably 0.01 to 20 ppm. In the present invention, for the purpose of dissolving the inorganic dirt, and improving the detergency and the sterilizing effect, (e) It is preferable to add a chelating agent as a component. Examples of the chelating agent include (1) tripolyphosphoric acid, pyrophosphoric acid, orthophosphoric acid, hexametaphosphoric acid and alkali metal salts thereof, (2) ethylenediaminetetraacetic acid, hydroxyiminodiacetic acid, dihydroxyethyldalicin, nitrilotriacetic acid, Hydroxyethylene diamine triacetic acid, diethylene triamine pentaacetic acid, triethylene tetramine hexaacetic acid and their metal salts or alkaline earth metal salts, (3) aminotrimethylene phosphonic acid, 1-hydroxyethylidene 1,1-diphosphonic acid, ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, N-oxide of aminotrimethylenephosphonic acid and alkali metal or alkaline earth metal salts thereof, (4) acrylic Select from acid and methacrylic acid Homopolymers or copolymers of monomers, acrylic acid-maleic acid copolymer, poly-α-hydroxyacrylic acid and its alkali metal salts, (5) citric acid, succinic acid, malic acid, fumaric acid, tartaric acid, At least one selected from the group consisting of polycarboxylic acids selected from malonic acid and maleic acid and alkali metal salts thereof; (6) alkyl glycine mono-, di-acetic acid, aspartic acid-Ν, di-acetic acid, and serine Mono-, di-acetic acid, glutamic acid diacetate, ethylenediamine disuccinic acid or salts thereof are preferred, and the compounds of (2), (3) and (5) are particularly preferred.
( e ) 成分は本発明の殺菌防汚洗浄剤中に好ましくは 0. 1〜20 重量%であり、 詳しくは トリガーやエアゾールなどの噴霧装置や、 塗布するような方法にて対象の硬質表面を洗浄 するような場合は、 (e ) 成分の濃度は 0. 1〜10重量%、 より好ましくは 0. 3〜7重量%で あり、 一方、 トイレタンク内の水を利用した洗浄方法において、 タンク内または任意の給 水経路に装置を設けることでタンク内の水に適量な洗浄液を投与することができるトイレ 用オートクリーナーに用いる場合は、 1〜20重量%、 より好ましくは 2〜20重量%含有され る。 なおトイレのタンク内の (e ) 成分の濃度は 0. 01〜20 p pmが好ましい。 The component (e) is preferably 0.1 to 20% by weight in the germicidal antifouling detergent of the present invention. More specifically, the hard surface of the object is sprayed with a trigger or aerosol, or by a method such as coating. In the case of washing, the concentration of the component (e) is 0.1 to 10% by weight, more preferably 0.3 to 7% by weight. On the other hand, in the washing method using water in the toilet tank, 1-20% by weight, more preferably 2-20% by weight when used in toilet auto cleaners that can supply an appropriate amount of cleaning liquid to the water in the tank by installing a device inside or in an optional water supply path It is contained. The concentration of the component (e) in the toilet tank is preferably 0.01 to 20 ppm.
本発明は、 p Hを調整する場合に p H調整剤を使用してもよい。 p H調整剤としては塩 酸や硫酸など無機酸や、 クェン酸、 コ八ク酸、 リンゴ酸、 フマル酸、 酒石酸、 マロン酸、 マレイン酸などの有機酸などの酸剤や、 水酸化ナトリウムや水酸化カリウム、 アンモニア やその誘導体、 モノエタノールアミンゃジエタノールァミン、 トリエタノールァミンなど のァミン塩など、 炭酸ナトリウム、 炭酸カリウムなどのアルカリ剤を、 単独もしくは複合 して用いても構わない。 また、 これらの酸剤とアルカリ剤を組み合わせて緩衝剤系として 用いても構わない。 .  The present invention may use a pH adjuster when adjusting pH. Examples of pH adjusters include inorganic acids such as hydrochloric acid and sulfuric acid, acid agents such as citric acid, co-octanoic acid, malic acid, fumaric acid, tartaric acid, malonic acid, and maleic acid; sodium hydroxide; Alkaline agents such as sodium carbonate and potassium carbonate, such as potassium hydroxide, ammonia and derivatives thereof, and amine salts such as monoethanolamine diethanolamine and triethanolamine, may be used alone or in combination. Further, these acid agents and alkali agents may be used in combination as a buffer system. .
本発明の硬表面用殺菌防汚洗浄剤は、 上記の p H調整剤により、 2 0でにぉける ^1が 2〜1 2になるように調整することが好ましく、 特に p H 3〜l 1になるようにすること が防汚効果の点から好ましい。  The hard surface sterilizing and antifouling detergent of the present invention is preferably adjusted by the above-mentioned pH adjuster so that ^ 1 in 20 becomes 2 to 12 and particularly pH 3 to 1 It is preferable to set it to 1 from the viewpoint of the antifouling effect.
本発明では使用時の付着性を持たせ使いやすさ向上の目的で、 水溶性高分子の 1種以上 を添加することが出来る。 水溶性高分子としては特に限定されるものではないが、 特開平 8 - 2 0 9 1 9 4号公報 6頁 1 0欄〜 7頁 1 1欄に記載の水溶性高分子から選ばれる 1種 以上が好ましい。  In the present invention, one or more water-soluble polymers can be added for the purpose of imparting adhesion during use and improving ease of use. The water-soluble polymer is not particularly limited, but may be one selected from water-soluble polymers described in JP-A-8-209194, page 6, column 10 to page 7, column 11. The above is preferred.
本発明の硬表面用殺菌防汚洗浄剤には、 上記成分の他に、 本発明の効果を損なわない範 囲で通常の洗浄剤に配合されている添加剤、 例えば香料、 抗菌剤、 粘度調整剤、 顔料、 染 料、 懸濁剤などを添加することができる。 また、 使用時の起泡性を高める目的で、 トルェ ンスルホン酸、 キシレンスルホン酸、 クメンスルホン酸、 ァルケエルコハク酸及びこれら のアル力リ金属塩などの起泡助剤から選ばれる 1種以上を添加することが出来る。  In addition to the above-mentioned components, the hard surface sterilizing and antifouling detergent of the present invention contains additives, such as fragrances, antibacterial agents, and viscosity modifiers, which are blended with ordinary detergents within a range that does not impair the effects of the present invention. Agents, pigments, dyes, suspending agents and the like can be added. In addition, for the purpose of enhancing the foaming property at the time of use, at least one selected from foaming aids such as toluene sulfonic acid, xylene sulfonic acid, cumene sulfonic acid, arkeel succinic acid, and metal salts of these metals is added. I can do it.
本発明を使用する際には、 (a ) 成分の重合体と (b ) 成分の殺菌化合物とを、 溶媒中に 一剤として溶解または分散させても、 任意成分との組み合わせによる、 任意の剤数にして も構わない。 また、 任意成分を組み合わせることにより、 水などの溶媒に対して、 直ちに 溶解する、 あるいは徐放性を付与した、 一剤以上の粉末や錠剤の形状で用いても構わない。 さらに、 (a) 成分と (b) 成分、 あるいは任意成分のいずれかが液状で他方が粉末などの 固体状で用いることもできる。 When the present invention is used, even if the polymer of the component (a) and the germicidal compound of the component (b) are dissolved or dispersed as a single agent in a solvent, any one of the optional agents may be used in combination with the optional component. In numbers No problem. One or more powders or tablets may be used in the form of one or more powders which can be immediately dissolved in a solvent such as water or provided with sustained release by combining optional components. Further, any one of the component (a) and the component (b) or the optional component may be used in a liquid state, and the other may be used in a solid state such as a powder.
本発明の殺菌防汚洗浄剤の使用時の形態は、 特に問わないが、 (a) 成分、 (b) 成分及 び任意成分を含有し残部が水の液体組成物であることが好ましく、 オートクリ一ナ一とし て用いる場合は、 ポリエチレングリコール、 ポリエチレングリコール脂肪酸エステル、 ポ リエチレングリコール脂肪酸ジエステル、 脂肪酸、 又は塩等の凝固剤を用いて固体状もし くはゲル状の組成物としてもよい。 水の含有量は液体組成物又はゲル状組成物の場合は好 ましくは 10〜98重量%、 より好ましくは 20〜 95重量%である。 固体状組成物の 場合は好ましくは 30%以下、 より好ましくは 20%以下である。 実施例  The form of the sterilizing and antifouling detergent of the present invention at the time of use is not particularly limited, but is preferably a liquid composition containing component (a), component (b) and optional components, with the balance being water. When used as a solid, a solid or gel composition may be formed using a coagulant such as polyethylene glycol, polyethylene glycol fatty acid ester, polyethylene glycol fatty acid diester, fatty acid, or salt. The content of water is preferably 10 to 98% by weight, more preferably 20 to 95% by weight in the case of a liquid composition or a gel composition. In the case of a solid composition, it is preferably at most 30%, more preferably at most 20%. Example
ぐ実施例 1 > Example 1>
表 1に示す組成の殺菌防汚洗浄剤を調製し、 その防汚性及び殺菌性について下記の方法 で評価した。 結果を表 1に示す。  A germicidal antifouling detergent having the composition shown in Table 1 was prepared, and its antifouling property and bactericidal property were evaluated by the following methods. Table 1 shows the results.
<防汚性の評価 >  <Evaluation of antifouling property>
(1) 易洗浄性  (1) Easy cleaning
殺菌防汚剤 lmLを、 面積 10 cm2の陶器タイル表面に塗布し、 5分間放置した後、 水After sterilizing antifouling agent LML, applied to porcelain tiles surface area 10 cm 2, left for 5 minutes, water
20 01111^を45° の角度で流速 25mL/秒の割合で流し、 乾燥させることを 5回繰り 返して行った後、 陶器タイル表面にスポット状にォレイン酸を 0. 5 g滴下する。 ォレイ ン酸を滴下した陶器タイルを、 ォレイン酸が流れないよう、 水槽の底に静置し、 陶器夕ィ ルに直接水がかからないよう、 静かに水槽中に水を満たしていく。 その際のォレイン酸が 陶器タイル表面から除去される面積の割合を判定し、 次の 5段階で評価した。 なお、 汚れ 落ちの%はモデル汚染板 5枚の平均値を採用した 20 Flow of 01111 ^ at an angle of 45 ° at a flow rate of 25 mL / sec, and drying is repeated 5 times. Then, 0.5 g of oleic acid is dropped on the surface of the ceramic tile in the form of spots. The pottery tiles with the drop of oleic acid are allowed to stand at the bottom of the tank so that the oleic acid does not flow, and the tank is gently filled with water so that the pottery tiles are not directly exposed to water. At that time, the ratio of the area where oleic acid was removed from the ceramic tile surface was determined, and evaluated in the following five steps. The percentage of dirt removal was the average value of five model contamination plates.
5 :汚れ落ちが 80 %以上である  5: Stain removal is 80% or more
4 :汚れ落ちが 60 %以上 80 %未満である  4: Stain removal is 60% or more and less than 80%
3 :汚れ落ちが 40%以上 60%未満である  3: Stain removal is 40% or more and less than 60%
2 :汚れ落ちが 20%以上 40 %未満である 2: Stain removal is 20% or more and less than 40%
1 :汚れ落ちが 20 %未満である。 1: Stain removal is less than 20%.
(2) 汚れ付着防止性  (2) Dirt adhesion prevention
市販の便器 (C 730 B、 東陶機器 (株) 製) を用い、 汚れの付きにくさの評価を行つ た。 即ち組成物で便器を洗浄し、 1週間放置した際の汚れの付きにくさを、 以下の基準を 基に肉眼で測定した。  Using a commercially available toilet bowl (C 730 B, manufactured by Tohoku Kiki Co., Ltd.), the evaluation of the difficulty of soiling was performed. That is, the toilet was washed with the composition, and the difficulty of attaching the stain after being left for one week was visually measured based on the following criteria.
(評価基準)  (Evaluation criteria)
◎:汚れが付いていない。 A: No dirt.
〇:汚れが僅かに付いている。 〇: Slightly adhered.
△:汚れが少し付いている。 Δ: Slightly adhered.
X :汚れがかなり付いている。 X: There is considerable dirt.
<殺菌性評価 >  <Evaluation of sterilization>
供試菌として大腸菌 (Es che r i ch i a c o l i : I FO 3972) と黄色ブド ゥ球菌 (S t aphy l ococ cu s aur eu s : I FO 12732) を用いた。 殺菌性試験は、表 1に示す殺菌防汚剤 2m 1中に 108〜 103個の細菌浮遊液 50 μ 1を 加えよく混合した後、 放置時間を 5分とした時の殺菌性を調べた。 放置後、 その混合液を 0. 1ml採取して 0. 9m 1の LP希釈液中に加えて十分混合し、 洗浄液の菌への影響 を低下させ、 次いでこの混合液を S CDLP寒天培地上に塗布し、 大腸菌は 37t:で 24 時間、 黄色ブドウ球菌は 37 °Cで 48時間培養する。 培養後の生育したコロニー数を数え る。 なお殺菌試験は、 同じ殺菌防汚剤について、 各放置時間毎にそれぞれ 5つの試験区に より行ない、 以下の評点で殺菌性を評価した。 Escherichia coli (IFO 3972) and Staphylococcus aureus (Staphylococcus cauruseus: IFO 12732) were used as test bacteria. The bactericidal test was conducted by adding 50 μl of 10 8 to 10 3 bacterial suspensions to 2 ml of the germicidal antifouling agent shown in Table 1 and mixing well. Was. After standing, the mixture 0.1 ml is collected and added to 0.9 ml of LP diluent and mixed well to reduce the effect of the washing solution on the bacteria, then this mixture is spread on S CDLP agar medium, and the E. coli is 37t: Incubate for 24 hours at 37 ° C for 48 hours. Count the number of grown colonies after culture. In the sterilization test, the same sterilizing and antifouling agent was tested in five test plots for each standing time, and the sterilizing property was evaluated according to the following scores.
なお、 前記規定以外の実験条件の詳細は、 防菌防黴ハンドブック (日本防菌防黴学会編、 技報堂出版) の P 686に記載されている浮遊試験法 (定量的検査法) に従う。  The details of the experimental conditions other than the above-mentioned rules conform to the floating test method (quantitative test method) described in P. 686 of the Bacterial and Fungicide Handbook (edited by the Japan Society of Bacterial and Fungicide, published by Gihodo).
〇:放置時間が 5分でのコロニー数が 104以下になる。 〇: The number of colonies becomes less than 10 4 in 5 minutes.
X:放置時間が 5分でのコロニー数が 104を超える 表中の成分は次の通りである。 X: The number of colonies exceeds 10 4 when the standing time is 5 minutes The components in the table are as follows.
'重合体 B:マーコート 550 [塩化ジァリルジメチルアンモニゥムとアクリルアミド(モ ル比 30/70)共重合体 (Ca 1 gon社製、 重量平均分子量 500万、 ゲルパーミエ ーシヨンクロマトグラムにより測定、 ポリエチレングリコールを標準として使用)] '重合体 A:マーコート 100 [塩化ジァリルジメチルアンモニゥムのホモポリマー (C a 1 gon社製、 重量平均分子量 40万、 ゲルパーミエーシヨンクロマトグラムで測定、 ポリエチレングリコールを標準として使用)]  'Polymer B: Mercoat 550 [diallyldimethylammonium chloride and acrylamide (mole ratio 30/70) copolymer (Ca1gon, weight average molecular weight 5,000,000, measured by gel permeation chromatogram, Polyethylene glycol is used as standard)] 'Polymer A: Mercoat 100 [Homopolymer of diaryldimethylammonium chloride (Ca1gon, weight average molecular weight 400,000, measured by gel permeation chromatogram) Use polyethylene glycol as standard)]
-重合体 C:マーコ一ト 280、 Ca l go n社製、 塩化ジァリルジメチルアンモニゥ ムとアクリル酸の共重合体  -Polymer C: Mercoto 280, manufactured by Calgon, a copolymer of diaryldimethylammonium chloride and acrylic acid
•重合体 D:アクリル酸 3. 59 g、 水 280 g、 35 %塩酸水溶液 32mlの溶液に N, N—ジメチルァミノプロピルメ夕クリル酸アミド 76. 41 gを冷却下添加し中和した 溶液を 70°Cまで加熱し、 窒素雰囲気下で重合開始剤 (和光純薬製 V— 50) を滴下し た。熟成後冷却し、有効分 18%の重合体を得た。重量平均分子量 40万、モノマー(a) / 〔モノマー (a) +モノマー (b)〕 =0. 9 (モル比)  • Polymer D: A solution obtained by adding 76.41 g of N, N-dimethylaminopropylmethacrylic acid amide to a solution of 3.59 g of acrylic acid, 280 g of water, and 32 ml of 35% aqueous hydrochloric acid under cooling, and neutralized. Was heated to 70 ° C., and a polymerization initiator (W-50, manufactured by Wako Pure Chemical Industries, Ltd.) was added dropwise under a nitrogen atmosphere. After aging, the mixture was cooled to obtain a polymer having an effective content of 18%. Weight average molecular weight 400,000, monomer (a) / [monomer (a) + monomer (b)] = 0.9 (molar ratio)
•殺菌性化合物 A:サニゾール C [ココアルキルジメチルペンジルアンモニゥムクロリ ド (花王 (株) 製)]  • Fungicidal compound A: Sanizole C [cocoalkyl dimethyl benzylammonium chloride (manufactured by Kao Corporation)]
-殺菌性化合物 B:コ一夕ミン D 10 P [ジデシルジメチルアンモニゥムクロリド (花 王 (株) 製)]  -Bactericidal compound B: Koyinmin D 10 P [didecyldimethylammonium chloride (manufactured by Kao Corporation)]
•殺菌性化合物 C:塩化べンゼトニゥム [和光試薬、 下記構造のカチオン化合物]  • Fungicidal compound C: Benzetonium chloride [Wako reagent, cationic compound with the following structure]
CI"
Figure imgf000013_0001
殺菌性化合物 D:塩化ォクチルジメチルベンザルゴニゥム
CI "
Figure imgf000013_0001
Fungicidal compound D: Octyl dimethyl benzalgonium chloride
AO :アンヒトール 2 ON [ラウリルジメチルアミンォキシド (花王 (株) 製)] AO: Amphitol 2 ON [Lauryl dimethylamine oxide (Kao Corporation)]
AG:アルキルダルコシド (直鎖アルキル基の炭素数が 12と 14の混合物、 糖平均縮 合度 1. 2 [縮合度 1と 2の混合物]) AG: Alkyl darcoside (a mixture of straight chain alkyl groups with 12 and 14 carbon atoms, average saccharide condensation degree 1.2 [mixture of condensation degrees 1 and 2])
• ES: EO平均付加モル数が.2. 2モルのポリオキシエチレンラウリルエーテル硫酸 •ベタイン: N—ラウロイルァミノプロピル一 N, N—ジメチル一 N—力ルポキシメチ ルアンモニゥムベタイン • E D TA- 4 N a :エチレンジァミン四酢酸四ナトリウム塩 • ES: Polyoxyethylene lauryl ether sulfate with an average number of moles of added EO of 2.2 moles • Betaine: N-lauroylaminopropyl-N, N-dimethyl-N-potoxymethylammonium betaine • ED TA-4 Na: Ethylenediaminetetraacetic acid tetrasodium salt
• p H調整剤:塩酸及び/又は水酸化ナトリウム (何れも水溶液で用いる)  • pH adjuster: hydrochloric acid and / or sodium hydroxide (all used in aqueous solution)
<実施例 2 > <Example 2>
表 2に示すトイレ用オートクリーナー組成物を調整し、 カツコ内の数値 (ppm) になるよ うにスポィ卜でトイレタンク内に投入し、 フラッシュを行った際の防汚性について下記の 方法で評価した。 結果を表 2に示す。  The toilet auto-cleaner composition shown in Table 2 was prepared and poured into a toilet tank with a spot so that the value in Kazuko (ppm) was obtained. The antifouling property when flushing was evaluated by the following method did. Table 2 shows the results.
<防汚性の評価 > <Evaluation of antifouling property>
( 1 ) 易洗浄性  (1) Easy cleaning
フラッシュを 1 0回行った後の便器 (C730B 東陶機器 (株) 製) を用いォレイン酸 0 . 5 gをスポット状に 5力所滴下し、 フラッシュをした後のォレイン酸が除去さ れる面積の割合を判定し、 次の 5段階で評価した。 なお、 汚れ落ちの評価は 5回の 平均値を採用した。  After flushing 10 times, 0.5 g of oleic acid was dropped in five spots using a toilet (C730B manufactured by Tohoku Kikai Co., Ltd.) in spots, and the area from which the oleic acid was removed after flushing Was evaluated and evaluated in the following five steps. The average of five measurements was used for the evaluation of dirt removal.
(評価基準は表 1と同様)  (Evaluation criteria are the same as Table 1.)
( 2 ) 汚れ付着防止性  (2) Dirt adhesion prevention
市販の便器 (C 7 3 0 B、 東陶機器 (株) 製) を用い、 汚れの付きにくさの評価 を行った。 即ち組成物で便器を洗浄し、 1週間放置した際の汚れの付きにくさを、 以下の 基準を基に肉眼で測定した。  A commercially available toilet bowl (C730B, manufactured by Tohoku Kikai Co., Ltd.) was used to evaluate the difficulty of getting dirty. That is, the toilet was washed with the composition, and the hardiness of the toilet when allowed to stand for one week was visually measured based on the following criteria.
(評価基準)  (Evaluation criteria)
◎:汚れが付いていない。 A: No dirt.
〇:汚れが僅かに付いている。 〇: Slightly adhered.
△:汚れが少し付いている。 Δ: Slightly adhered.
X :汚れがかなり付いている。 X: There is considerable dirt.
( 3 ) 細菌の発育抑制効果  (3) Bacterial growth inhibitory effect
表 2のカツコ内の濃度に調整した組成物 2 ml に 104cfu/ral に調整した Staphylococcus aureusの懸濁液 0. 05ml と SCD培地 0. lmlを加えよく拡販し、 3 7。Cで 1 8時間静置し、 以下のような式で静菌活性値を求めた。 Table 2 of well sales added a suspension 0. 05Ml and SCD medium 0. lml of Staphylococcus aureus which had been adjusted to 10 4 cfu / ral to adjust the composition 2 ml concentration in Katsuko, 3 7. After standing at C for 18 hours, the bacteriostatic activity value was determined by the following formula.
なお、 ブランクとしては滅菌水を用いた。 静菌活性値 = log (ブランクの培養後の生菌数) —log (評価サンプル培養後の生菌数) <評価〉 Sterile water was used as a blank. Bacteriostatic activity value = log (number of viable cells after blank culture)-log (number of viable cells after culture of evaluation sample) <evaluation>
〇:静菌活性値: 0より大きい  〇: Bacteriostatic activity value: greater than 0
X :静菌活性値: 0以下 X: Bacteriostatic activity value: 0 or less
配合例 Formulation example
 One
1 . o 4 Ό D 1 b y I o u "r α o 1 Ί o 20 1. O 4 Ό D 1 by I o u "r α o 1 Ί o 20
M口 1 A n U. u. M mouth 1 A n U. u.
里番ム σ / 1女小 tit 0.1 0.3 1 3  Satoban Mu σ / 1 female small tit 0.1 0.3 1 3
(a)成分  (A) component
坐口 1平し 0.1 0.3 1 ■) 1 1 1 3  Sitting mouth 1 flat 0.1 0.3 1 ■) 1 1 1 3
ム女 n Woman n
里 α 1小 U 0.1 1 1 5 3 ネ又困 Ί土 1 C口 ク JA 0.01 1 0.1 0.3 1 0.05 0.1 0.1 0.1 0.05 殺菌性化合物 Β 0.3 0.3  Sato α 1 small U 0.1 1 1 5 3 Neither soil 1 C mouth JA 0.01 1 0.1 0.3 1 0.05 0.1 0.1 0.1 0.05 Fungicidal compound Β 0.3 0.3
硬 (b)成分  Hard (b) component
殺菌性化合物 C 1  Fungicidal compound C 1
殺菌性化合物 D 0.1 0.3 0.5 1 1 0.5 1 1 2 Fungicidal compound D 0.1 0.3 0.5 1 1 0.5 1 1 2
AO 1 1 1 1 1 1 2 ' 1 1 1 AO 1 1 1 1 1 1 2 '1 1 1
AG 1 3 1 1 1 1 1 3 1 1 1 3 1 1 1.5 1 0.5 AG 1 3 1 1 1 1 1 3 1 1 1 3 1 1 1.5 1 0.5
(c)成分 (c) ingredient
ぺ'タイン 1 1 1 1 1 1 1 1 1 1 1 0.5 1 ぺ 'tine 1 1 1 1 1 1 1 1 1 1 1 0.5 1
ES 0.5 0.5 0.3 0.5 エタノ-ル 3 3 5 3 3 3 2 5 5 5 5 2 5 5 2 フ'ロビレンゲリコール 3 5 5 3 3 ES 0.5 0.5 0.3 0.5 Ethanol 3 3 5 3 3 3 2 5 5 5 5 2 5 5 2 Phylobilenguelicol 3 5 5 3 3
(d)成分 5 3 (d) Component 5 3
Jim ブロビレンゲリコ—ルモノメ Jim Brovilengeliko
5  Five
チルエーテル  Chill ether
クエリ酸 2 2 2 5 1 1 1 1 2 2 4 2 2 2 2 5 2 2 Query acid 2 2 2 5 1 1 1 1 2 2 4 2 2 2 2 5 2 2
( 成分 (Ingredients
EDTA- 4N a 3 3 3 2 2 5 2 2 2 3 3 3 イオン交換水 残部残部残部残部残部残部残部残部残部残部残部残部残部残部残部残部残部残部残部残部 合計 100 100 100 100 100 100 100 100 100 100 100 1.00 100 100 100 100 100 100 100 100 pH 7 7 11 3 7 7 7 7 7 7 7 7 3 10 7 7 7 3 6 6 易洗浄性 4.0 5.0 5.0 5.0 4.0 5.0 5.0 5.0 4.6 5.0 5.0 5.0 4.6 4.6 5.0 5.0 4.2 4.2 5.0 5.0 汚れ付着防止性 〇 ◎ ◎ ◎ 〇 ◎ ◎ ◎ 〇 ◎ ◎ ◎ ◎ ◎ ◎ ◎ 〇 〇 ◎ ◎ 殺菌性 〇 〇 〇 O 〇 〇 〇 〇 O 〇 〇 〇 〇 o Ο 〇 〇 〇 〇 〇 EDTA- 4N a 3 3 3 2 2 5 2 2 2 3 3 3 Ion-exchanged water Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining Total 100 100 100 100 100 100 100 100 100 100 100 1.00 100 100 100 100 100 100 100 100 pH 7 7 11 3 7 7 7 7 7 7 7 7 3 10 7 7 7 3 6 6 Easy cleaning 4.0 5.0 5.0 5.0 4.0 5.0 5.0 5.0 4.6 5.0 5.0 5.0 4.6 4.6 5.0 5.0 4.2 4.2 5.0 5.0 Anti-fouling properties 〇 ◎ ◎ ◎ 〇 ◎ ◎ ◎ 〇 ◎ ◎ ◎ ◎ ◎ ◎ ◎ ◎ 〇 〇 ◎ ◎ Sterilization
瑯 ¾ £ 瑯 ¾
比 ϋ .配合例 Comparison example
1 2 3 4 5 6 フ 重合体 A 1  1 2 3 4 5 6 F Polymer A 1
重合体 B 1  Polymer B 1
(a)成分  (A) component
重合体 C 1  Polymer C 1
重合体 D 1 殺菌性化合物 A 0.1  Polymer D 1 Fungicidal compound A 0.1
殺菌性化合物 B 0.3  Bactericidal compound B 0.3
硬 (b〉成分  Hard (b) component
殺菌 1生化合物 G  Sterilization 1 Raw compound G
質配  Pledge
表 ネ ¾_菌1玍化 n物 D 1 1 面成 AO 1 用 分  Table ¾ _ Bacteria monomerized n D 1 1 AO 1
1.5 1 1 殺 ' *~、  1.5 1 1 kill '* ~,
(c)成分 η  (c) component η
菌 ヘ メ 1ノ 1 U.0 1 1 防量 ES  Bacterium 1 1 U.0 1 1 ES
汚 %  Dirty%
エタノ-ル  Ethanol
 Washing
浄 (d)成分フ'ロビレンゲリコマル 5 ο  Pure (d) Ingredients
剤 プロピレンゲリコールモノメ  Agent Propylene gericol monomer
チルエーテル  Chill ether
クェン酸 1 1 2 2 2 Cuenoic acid 1 1 2 2 2
(e)成分 (e) component
EDTA- 4Na 2 3 . 5 2 イオン交換水 残部残部残部残部残部残部残部 EDTA-4Na 2 3.5 2 Ion-exchanged water Remaining Remaining Remaining Remaining Remaining Remaining Remaining Remaining
C3。丁 100 100 100 100 100 100 100C3. 100 100 100 100 100 100 100
ΡΗ . 7 . 7 7 7 7 7 7 易洗浄性 2.0 1.0 2.0 2.0 2.0 2.0 2.4 汚れ付着防止性 △ X Δ X X X XΡΗ. 7.7 7 7 7 7 7 7 Easy cleaning 2.0 1.0 2.0 2.0 2.0 2.0 2.4 Stain adhesion prevention △ X Δ X X X X
¥£菌性 X X X X 〇 X X ¥ £ Bacterial XXXX 〇 XX
表 2 Table 2
Figure imgf000017_0001
Figure imgf000017_0001
-15- -15-

Claims

請求の範囲 The scope of the claims
1. (a) 重量平均分子量が 1, 000〜 6, 000, 000であって、 4級アンモニ ゥム基及び 3級ァミノ基より選ばれた少なくとも 1ケの基を有するモノマ一単位をその比 率が全モノマー単位に対して 10~100モル%含む重合体、 (b) 分子量が 1, 000未 満であって、 4級アンモニゥム基を有する殺菌性化合物、 及び (c) 界面活性剤を含有し、 界面活性剤として (cA) 陰イオン界面活性剤を含有する場合、 (cA) / (b) が重量比 率で、 1. 0を越えない硬質表面用殺菌防汚洗浄剤。 1. (a) A monomer unit having a weight average molecular weight of 1,000 to 6,000,000 and having at least one group selected from quaternary ammonium groups and tertiary amino groups (B) a bactericidal compound having a molecular weight of less than 1,000 and having a quaternary ammonium group, and (c) a surfactant. When (cA) an anionic surfactant is contained as a surfactant, a (cA) / (b) weight ratio of (cA) / (b) does not exceed 1.0, which is a bactericidal and antifouling detergent for hard surfaces.
2. (b) が下記式 (1) 〜 (3) で表される化合物から選ばれる少なくとも一種の殺 菌性化合物である請求項 1記載の硬質表面用殺菌防汚洗浄剤。 2. The germicidal and antifouling detergent for hard surfaces according to claim 1, wherein (b) is at least one bactericidal compound selected from the compounds represented by the following formulas (1) to (3).
Figure imgf000018_0001
Figure imgf000018_0001
Figure imgf000018_0002
Figure imgf000018_0002
Figure imgf000018_0003
Figure imgf000018_0003
〔式中、 R1及び R6は、 それぞれ独立して炭素数 6〜18のアルキル基又はアルケニル基 であり、 1 3及び14は、 それぞれ独立して炭素数 1~ 3のアルキル基又はヒドロキシアル キル基である。 Xは芳香環又は— COO—、 一 CONH—、 一OCO—、 —NHCO—か ら選ばれるエステル基あるいはアミド基であり、 R2は、 Xがエステル基又はアミド基であ る場合には水酸基で置換されていてもよい炭素数 1〜 6のアルキレン基であり、 Xが芳香 環の場合には、 水酸基で置換されていてもよい炭素数 1〜6のアルキレン基又は一(O— R n)k—である。 ここで R11はエチレン基又はプロピレン基であり、 kは平均 1〜10の数 である。 R5は炭素数 1〜3のアルキレン ¾である。 !¾7〜1^1 )はこれらの内1っ以上が炭 素数 8~18のアルキル基であり、 残りが炭素数 1~3のアルギル基又はヒドロキシアル キル基である。 また、 mは 0又は 1の数である。 さらに Y—は、 陰イオンである。〕 Wherein, R 1 and R 6 are each independently an alkyl group or alkenyl group having 6 to 18 carbon atoms, 1 3 and 1 4 are each independently alkyl or hydroxyalkyl of 1 to 3 carbon atoms It is an alkyl group. X is an aromatic ring or an ester group or an amide group selected from —COO—, one CONH—, one OCO—, and —NHCO—, and R 2 is a hydroxyl group when X is an ester group or an amide group. And when X is an aromatic ring, an alkylene group having 1 to 6 carbon atoms which may be substituted with a hydroxyl group or one (O—R n ) k —. Here, R 11 is an ethylene group or a propylene group, and k is a number of 1 to 10 on average. R 5 is alkylene having 1 to 3 carbon atoms. ! ¾ 7 to 1 ^ 1) is an alkyl group of 1 Tsu or more of these carbon number 8 to 18, the remainder being Argyle or hydroxy aralkyl kill groups of 1 to 3 carbon atoms. M is a number of 0 or 1. Furthermore, Y— is an anion. ]
3. (a) の 4級アンモニゥム基を有するモノマー単位が下記式 (4) の化合物に由来 する請求項 1記載の硬質表面用殺菌防汚洗浄剤。 3. The germicidal and antifouling detergent for hard surfaces according to claim 1, wherein the monomer unit having a quaternary ammonium group in (a) is derived from a compound represented by the following formula (4).
Figure imgf000018_0004
Figure imgf000018_0004
-16- 〔式中、 R12、 R13、 R14は、 それぞれ独立して、 7K素原子、 水酸基又は炭素数 1~3の アルキル基である。 Xは炭素数 1〜12のアルキレン基、 —COOR18—、 -CONHR1 8—、 一 OCOR18—、 一 R19— OC〇一 R18—から選ばれる基である。 ここで R18、 R 19は、 それぞれ独立して、 炭素数 1〜5のアルキレン基である。 1¾15は炭素数1〜3のァ ルキル基もしくはヒドロキシアルキル基又は R12R13C = C (R14)一 X—である。 R16 は炭素数 1~3のアルキル基、 ヒドロキシアルキル基、 ベンジル基であり、 R 17はヒドロ キシ基、 力ルポキシル基、 スルホン酸基、 硫酸エステル基で置換されていてもよい炭素数 1~10のアルキル基、 又はべンジル基であり、 R17がアルキル基、 ヒドロキシアルキル 基、 又はべンジル基の場合は、 Y—は陰イオンを示す。〕 -16- [Wherein, R 12 , R 13 and R 14 are each independently a 7K element atom, a hydroxyl group or an alkyl group having 1 to 3 carbon atoms. X is an alkylene group having 1 to 12 carbon atoms, -COOR 18 -, -CONHR 1 8 - one OCOR 18 - a group selected from - one R 19 - OC_〇 one R 18. Here, R 18 and R 19 are each independently an alkylene group having 1 to 5 carbon atoms. 1 to 15 are an alkyl group or hydroxyalkyl group having 1 to 3 carbon atoms or R 12 R 13 C = C (R 14 ) -X—. R 16 is an alkyl group having 1 to 3 carbon atoms, a hydroxyalkyl group, or a benzyl group; and R 17 is a C 1 to C 3 group which may be substituted with a hydroxy group, a carbonyl group, a sulfonic acid group, or a sulfate group. When R 17 is an alkyl group, a hydroxyalkyl group, or a benzyl group, Y— represents an anion. ]
4. (a) の 3級アミノ基を有するモノマー単位が下記式 (5) で示される化合物に由 来する請求項 1記載の硬質表面用殺菌防汚洗浄剤。 4. The germicidal and antifouling detergent for hard surfaces according to claim 1, wherein the monomer unit having a tertiary amino group in (a) is derived from a compound represented by the following formula (5).
R15 (5) R 15 (5)
R12R13c_cf R14 ノ R 12 R 13 c _ cf R 14 no
■X— N  ■ X—N
R16 R 16
[式中、 R.12、 R13、 R14、 R15及び R16は、 前記記載と同じ。〕 Wherein, R. 12, R 13, R 14, R 15 and R 16 are the same as above described. ]
5. (a) 成分の重合体が 4級アンモニゥム基及び 3級ァミノ基より選ばれた少なく とも 1ケの基を有するモノマ一単位 A及びカルボン酸基およびスルホン酸基から選ばれた 少なくとも 1つの基を有する [但し 4級アンモニゥム基を有さない] モノマー単位 B' を 含み、 かつモノマ一単位 Aと B, の合計が全モノマー単位に対して 50~100モル%を 占める重合体である請求項 1記載の硬質表面用殺菌防汚洗浄剤。 5. (a) The polymer of component is a monomer unit A having at least one group selected from quaternary ammonium groups and tertiary amino groups, and at least one selected from carboxylic acid groups and sulfonic acid groups. Is a polymer containing a monomer unit B 'having a group [but not having a quaternary ammonium group] and wherein the sum of monomer units A and B accounts for 50 to 100 mol% of all monomer units. Item 6. The sterilizing and antifouling detergent for hard surfaces according to Item 1.
6. (a)成分を 0. 01~30重量%、 (b)成分を 0. 001 ~ 30重量%及び( c ) 成分を 0. 01〜 50重量%含有する請求項 1記載の硬質表面用殺菌防汚洗狰剤。 6. The hard surface according to claim 1, wherein the component (a) contains 0.01 to 30% by weight, the component (b) contains 0.001 to 30% by weight, and the component (c) contains 0.01 to 50% by weight. Sterilizing and antifouling detergent.
7. 請求項 1に記載した辑成物を硬質表面に適用することにより硬質表面を洗浄し殺 菌し、 そして硬質表面への汚れの付着を防止する方法。 7. A method for cleaning and disinfecting a hard surface by applying the composition according to claim 1 to the hard surface and preventing adhesion of dirt to the hard surface.
8. 請求項 1に記載した組成物を硬質表面を洗铮し、 殺菌しそして硬質表面への汚れ の付着を防止する用途。 8. Use of the composition according to claim 1 for cleaning and disinfecting hard surfaces and preventing the adhesion of dirt to hard surfaces.
■ 17- ■ 17-
PCT/JP2001/006869 2000-08-23 2001-08-09 Bactericidal antifouling detergent for hard surface WO2002016536A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-252284 2000-08-23
JP2000252284A JP2002060786A (en) 2000-08-23 2000-08-23 Germicidal stainproofing agent for hard surface

Publications (1)

Publication Number Publication Date
WO2002016536A1 true WO2002016536A1 (en) 2002-02-28

Family

ID=18741548

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/006869 WO2002016536A1 (en) 2000-08-23 2001-08-09 Bactericidal antifouling detergent for hard surface

Country Status (3)

Country Link
JP (1) JP2002060786A (en)
TW (1) TWI283267B (en)
WO (1) WO2002016536A1 (en)

Cited By (270)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070866A1 (en) * 2002-02-22 2003-08-28 Kao Corporation Antifouling detergent for hard surfaces
WO2005014791A2 (en) 2003-08-08 2005-02-17 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
JP2005232241A (en) * 2004-02-18 2005-09-02 Toyo Aluminium Foil Products Kk Coating agent for removing greasy dirt
US7544649B2 (en) 2002-02-22 2009-06-09 Kao Corporation Antifouling detergent for hard surfaces
WO2009151591A2 (en) 2008-06-10 2009-12-17 Sangamo Biosciences, Inc. Methods and compositions for generation of bax- and bak-deficient cell lines
WO2010021692A1 (en) 2008-08-22 2010-02-25 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
WO2010065123A1 (en) 2008-12-04 2010-06-10 Sangamo Biosciences, Inc. Genome editing in rats using zinc-finger nucleases
WO2010077319A1 (en) 2008-12-17 2010-07-08 Dow Agrosciences Llc Targeted integration into the zp15 locus
EP2206782A1 (en) 2006-05-25 2010-07-14 Sangamo BioSciences, Inc. Methods and compositions for gene inactivation
EP2213731A1 (en) 2006-05-25 2010-08-04 Sangamo BioSciences, Inc. Variant foki cleavage half-domains
WO2010090744A1 (en) 2009-02-04 2010-08-12 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathies
WO2011002503A1 (en) 2009-06-30 2011-01-06 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
EP2292274A1 (en) 2004-09-16 2011-03-09 Sangamo BioSciences, Inc. Compositions and methods for protein production
US7919313B2 (en) 2007-07-12 2011-04-05 Sangamo Biosciences, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
EP2395081A1 (en) 2006-08-11 2011-12-14 Dow AgroSciences LLC Zinc finger nuclease-mediated homologous recombination
WO2012012667A2 (en) 2010-07-21 2012-01-26 Sangamo Biosciences, Inc. Methods and compositions for modification of a hla locus
EP2412812A1 (en) 2006-12-14 2012-02-01 Dow AgroSciences LLC Optimized non-canonical zinc finger proteins
US8110379B2 (en) 2007-04-26 2012-02-07 Sangamo Biosciences, Inc. Targeted integration into the PPP1R12C locus
US8153399B2 (en) 2008-10-29 2012-04-10 Sangamo Biosciences, Inc. Methods and compositions for inactivating glutamine synthetase gene expression
WO2012047598A1 (en) 2010-09-27 2012-04-12 Sangamo Biosciences, Inc. Methods and compositions for inhibiting viral entry into cells
WO2012051343A1 (en) 2010-10-12 2012-04-19 The Children's Hospital Of Philadelphia Methods and compositions for treating hemophilia b
US8313925B2 (en) 2005-07-26 2012-11-20 Sangamo Biosciences, Inc. Zinc finger proteins and method for inactivating a dhfr gene in a chinese hamster ovary cell
US8399218B2 (en) 2007-09-27 2013-03-19 Dow Agrosciences, Llc Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
WO2013044008A2 (en) 2011-09-21 2013-03-28 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
EP2597155A1 (en) 2007-10-25 2013-05-29 Sangamo BioSciences, Inc. Methods and compositions for targeted integration
EP2615106A1 (en) 2010-02-08 2013-07-17 Sangamo BioSciences, Inc. Engineered cleavage half-domains
WO2013130824A1 (en) 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
EP2660318A1 (en) 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
WO2013166315A1 (en) 2012-05-02 2013-11-07 Dow Agrosciences Llc Targeted modification of malate dehydrogenase
WO2013169802A1 (en) 2012-05-07 2013-11-14 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
US8592645B2 (en) 2009-10-22 2013-11-26 Dow Agrosciences Llc Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
WO2014011901A2 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
WO2014011237A1 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
WO2014036219A2 (en) 2012-08-29 2014-03-06 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
WO2014039692A2 (en) 2012-09-07 2014-03-13 Dow Agrosciences Llc Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
WO2014039872A1 (en) 2012-09-07 2014-03-13 Dow Agrosciences Llc Engineered transgene integration platform (etip) for gene targeting and trait stacking
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
EP2727600A1 (en) 2009-07-28 2014-05-07 Sangamo BioSciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
US8771985B2 (en) 2010-04-26 2014-07-08 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using zinc-finger nucleases
US8772453B2 (en) 2010-05-03 2014-07-08 Sangamo Biosciences, Inc. Compositions for linking zinc finger modules
WO2014130955A1 (en) 2013-02-25 2014-08-28 Sangamo Biosciences, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
WO2014165612A2 (en) 2013-04-05 2014-10-09 Dow Agrosciences Llc Methods and compositions for integration of an exogenous sequence within the genome of plants
US8871905B2 (en) 2009-03-20 2014-10-28 Sangamo Biosciences, Inc. Modification of CXCR4 using engineered zinc finger proteins
US8895264B2 (en) 2011-10-27 2014-11-25 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2015031619A1 (en) 2013-08-28 2015-03-05 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
WO2015057976A1 (en) 2013-10-17 2015-04-23 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
WO2015057980A1 (en) 2013-10-17 2015-04-23 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2015066643A1 (en) 2013-11-04 2015-05-07 Dow Agrosciences Llc Optimal soybean loci
WO2015066636A2 (en) 2013-11-04 2015-05-07 Dow Agrosciences Llc Optimal maize loci
WO2015066638A2 (en) 2013-11-04 2015-05-07 Dow Agrosciences Llc Optimal maize loci
WO2015070212A1 (en) 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
US9045763B2 (en) 2005-07-26 2015-06-02 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
WO2015117081A2 (en) 2014-02-03 2015-08-06 Sangamo Biosciences, Inc. Methods and compositions for treatment of a beta thalessemia
WO2015130931A1 (en) 2014-02-28 2015-09-03 Dow Agrosciences Llc Root specific expression conferred by chimeric gene regulatory elements
WO2015143046A2 (en) 2014-03-18 2015-09-24 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
US9161995B2 (en) 2011-07-25 2015-10-20 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
EP2936976A1 (en) 2008-04-21 2015-10-28 Danziger Innovations Ltd. Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
EP2947146A1 (en) 2004-02-05 2015-11-25 Sangamo BioSciences, Inc. Methods and compositions for targeted cleavage and recombination
US9217026B2 (en) 2006-11-13 2015-12-22 Sangamo Biosciences, Inc. Method of inactivating a glucocorticoid receptor gene in an isolated cell
WO2016005449A1 (en) 2014-07-08 2016-01-14 Vib Vzw Means and methods to increase plant yield
WO2016011381A1 (en) 2014-07-18 2016-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells
WO2016011029A2 (en) 2014-07-14 2016-01-21 Washington State University Nanos knock-out that ablates germline cells
US9249428B2 (en) 2003-08-08 2016-02-02 Sangamo Biosciences, Inc. Methods and compositions for targeted genomic deletion
US9255250B2 (en) 2012-12-05 2016-02-09 Sangamo Bioscience, Inc. Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
US9267123B2 (en) 2011-01-05 2016-02-23 Sangamo Biosciences, Inc. Methods and compositions for gene correction
WO2016044416A1 (en) 2014-09-16 2016-03-24 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
US9394531B2 (en) 2008-05-28 2016-07-19 Sangamo Biosciences, Inc. Compositions for linking DNA-binding domains and cleavage domains
WO2016118726A2 (en) 2015-01-21 2016-07-28 Sangamo Biosciences, Inc. Methods and compositions for identification of highly specific nucleases
US9458205B2 (en) 2011-11-16 2016-10-04 Sangamo Biosciences, Inc. Modified DNA-binding proteins and uses thereof
WO2016161446A1 (en) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2016168229A1 (en) 2015-04-15 2016-10-20 Dow Agrosciences Llc Plant promoter for transgene expression
WO2016168230A2 (en) 2015-04-15 2016-10-20 Dow Agrosciences Llc Plant promoter for transgene expression
WO2016178207A1 (en) 2015-05-04 2016-11-10 Ramot At Tel-Aviv University Ltd. Methods and kits for fragmenting dna
US9506120B2 (en) 2007-09-27 2016-11-29 Sangamo Biosciences, Inc. Rapid in vivo identification of biologically active nucleases
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
WO2017011519A1 (en) 2015-07-13 2017-01-19 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2017023570A1 (en) 2015-08-06 2017-02-09 The Curators Of The University Of Missouri Pathogen-resistant animals having modified cd163 genes
US9574211B2 (en) 2014-05-13 2017-02-21 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
WO2017053164A1 (en) 2015-09-22 2017-03-30 Dow Agrosciences Llc Plant promoter and 3' utr for transgene expression
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
EP3156504A1 (en) 2009-08-11 2017-04-19 Sangamo BioSciences, Inc. Organisms homozygous for targeted modification
WO2017070298A1 (en) 2015-10-22 2017-04-27 Dow Agrosciences Llc Plant promoter for transgene expression
WO2017079673A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
WO2017078935A1 (en) 2015-11-04 2017-05-11 Dow Agrosciences Llc Plant promoter for transgene expression
WO2017106537A2 (en) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the mhc cell receptor
WO2017106528A2 (en) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the t cell receptor
WO2017123757A1 (en) 2016-01-15 2017-07-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
US9757420B2 (en) 2014-07-25 2017-09-12 Sangamo Therapeutics, Inc. Gene editing for HIV gene therapy
US9771403B2 (en) 2013-12-09 2017-09-26 Sangamo Therapeutics, Inc. Methods and compositions for treating hemophilia
WO2017165655A1 (en) 2016-03-23 2017-09-28 Dana-Farber Cancer Institute, Inc. Methods for enhancing the efficiency of gene editing
WO2017180180A2 (en) 2015-09-22 2017-10-19 Dow Agrosciences Llc Plant promoter and 3' utr for transgene expression
US9816074B2 (en) 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
US9834787B2 (en) 2009-04-09 2017-12-05 Sangamo Therapeutics, Inc. Targeted integration into stem cells
WO2018005559A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
WO2018005556A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
WO2018013840A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
US9873894B2 (en) 2013-05-15 2018-01-23 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
WO2018029034A1 (en) 2016-08-09 2018-02-15 Vib Vzw Cellulose synthase inhibitors and mutant plants
WO2018039448A1 (en) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Engineered target specific nucleases
WO2018039440A1 (en) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Regulation of gene expression using engineered nucleases
US9914930B2 (en) 2012-09-07 2018-03-13 Dow Agrosciences Llc FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
WO2018067826A1 (en) 2016-10-05 2018-04-12 Cellular Dynamics International, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
WO2018067265A1 (en) 2016-10-03 2018-04-12 Dow Agrosciences Llc Plant promoter for transgene expression
WO2018067264A1 (en) 2016-10-03 2018-04-12 Dow Agrosciences Llc Plant promoter for transgene expression
WO2018067618A1 (en) 2016-10-03 2018-04-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2018071873A2 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
WO2018081775A1 (en) 2016-10-31 2018-05-03 Sangamo Therapeutics, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
US9970001B2 (en) 2014-06-05 2018-05-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease design
WO2018102612A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
WO2018106782A1 (en) 2016-12-08 2018-06-14 Case Western Reserve University Methods and compositions for enhancing functional myelin production
WO2018106732A1 (en) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
WO2018195418A1 (en) 2017-04-20 2018-10-25 Oregon Health & Science University Human gene correction
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
GB201820109D0 (en) 2018-12-11 2019-01-23 Vib Vzw Plants with a lignin trait and udp-glycosyltransferase mutation
US10233465B2 (en) 2013-11-04 2019-03-19 Dow Agrosciences Llc Optimal soybean loci
WO2019070541A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. Hpv-specific binding molecules
US10260062B2 (en) 2010-01-22 2019-04-16 Sangamo Therapeutics, Inc. Targeted genomic alteration
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
EP3492593A1 (en) 2013-11-13 2019-06-05 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
WO2019143677A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
WO2019143675A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2019143678A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US10370680B2 (en) 2014-02-24 2019-08-06 Sangamo Therapeutics, Inc. Method of treating factor IX deficiency using nuclease-mediated targeted integration
US10415046B2 (en) 2012-12-13 2019-09-17 Dow Agrosciences Llc Precision gene targeting to a particular locus in maize
WO2019191495A1 (en) 2018-03-29 2019-10-03 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
US10435441B2 (en) 2015-09-23 2019-10-08 Sangamo Therapeutics, Inc. HTT repressors and uses thereof
WO2019195491A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
WO2019195492A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
WO2019215500A1 (en) 2018-05-11 2019-11-14 Crispr Therapeutics Ag Methods and compositions for treating cancer
WO2019234750A1 (en) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Methods of regenerating and transforming cannabis
WO2019234141A1 (en) 2018-06-06 2019-12-12 Vib Vzw NOVEL MUTANT PLANT CINNAMOYL-CoA REDUCTASE PROTEINS
WO2019234754A1 (en) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Nucleic acid constructs and methods of using same
US10507232B2 (en) 2014-04-02 2019-12-17 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
US10612041B2 (en) 2014-03-21 2020-04-07 The Board Of Trustees Of The Leland Stanford Junior University Genome editing without nucleases
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US10639383B2 (en) 2015-11-23 2020-05-05 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
WO2020095248A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-ptk7 immune cell cancer therapy
WO2020095249A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-liv1 immune cell cancer therapy
WO2020095107A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
WO2020118073A1 (en) 2018-12-05 2020-06-11 Vertex Pharmaceuticals Incorporated Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene
US10724020B2 (en) 2016-02-02 2020-07-28 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2020185628A1 (en) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Cd40l compositions and methods for tunable regulation
US10786533B2 (en) 2015-07-15 2020-09-29 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2020205838A1 (en) 2019-04-02 2020-10-08 Sangamo Therapeutics, Inc. Methods for the treatment of beta-thalassemia
US10808020B2 (en) 2015-05-12 2020-10-20 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
WO2020219726A1 (en) 2019-04-23 2020-10-29 Sangamo Therapeutics, Inc. Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
WO2020223571A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
WO2020223535A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
US10858628B2 (en) 2015-11-04 2020-12-08 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2020261219A1 (en) 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
WO2021022223A1 (en) 2019-08-01 2021-02-04 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
US10927346B2 (en) 2017-12-22 2021-02-23 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof
WO2021041316A1 (en) 2019-08-23 2021-03-04 Sana Biotechnology, Inc. Cd24 expressing cells and uses thereof
WO2021044378A1 (en) 2019-09-06 2021-03-11 Crispr Therapeutics Ag Genetically engineered t cells having improved persistence in culture
US10960085B2 (en) 2016-09-07 2021-03-30 Sangamo Therapeutics, Inc. Modulation of liver genes
WO2021067871A1 (en) 2019-10-02 2021-04-08 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for repressing alpha-synuclein expression
WO2021067864A1 (en) 2019-10-02 2021-04-08 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for treatment of prion disease
WO2021087366A1 (en) 2019-11-01 2021-05-06 Sangamo Therapeutics, Inc. Compositions and methods for genome engineering
WO2021087358A1 (en) 2019-11-01 2021-05-06 Sangamo Therapeutics, Inc. Gin recombinase variants
EP3839050A2 (en) 2012-04-18 2021-06-23 The Board of Trustees of the Leland Stanford Junior University Non-disruptive gene targeting
EP3838287A2 (en) 2016-07-27 2021-06-23 Case Western Reserve University Compounds and methods of promoting myelination
WO2021142376A1 (en) 2020-01-08 2021-07-15 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
WO2021151012A1 (en) 2020-01-22 2021-07-29 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for repressing tau expression
WO2021155065A1 (en) 2020-01-28 2021-08-05 The Broad Institute, Inc. Base editors, compositions, and methods for modifying the mitochondrial genome
US11110154B2 (en) 2014-05-08 2021-09-07 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
WO2021195426A1 (en) 2020-03-25 2021-09-30 Sana Biotechnology, Inc. Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
US11155796B2 (en) 2015-02-09 2021-10-26 Duke University Compositions and methods for epigenome editing
WO2021224395A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
WO2021224416A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
WO2021231661A2 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
WO2021236852A1 (en) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
US11219695B2 (en) 2016-10-20 2022-01-11 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of Fabry disease
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
WO2022036150A1 (en) 2020-08-13 2022-02-17 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
WO2022046760A2 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
WO2022064428A1 (en) 2020-09-23 2022-03-31 Crispr Therapeutics Ag Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
WO2022067122A1 (en) 2020-09-25 2022-03-31 Sangamo Therapeutics, Inc. Zinc finger fusion proteins for nucleobase editing
WO2022072826A1 (en) 2020-10-02 2022-04-07 Sangamo Therapeutics, Inc. Novel zinc finger protein transcription factors for repressing alpha-synuclein expression
WO2022098787A1 (en) 2020-11-04 2022-05-12 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
WO2022101641A1 (en) 2020-11-16 2022-05-19 Pig Improvement Company Uk Limited Influenza a-resistant animals having edited anp32 genes
WO2022120334A1 (en) 2020-12-03 2022-06-09 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
WO2022137181A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
WO2022146891A2 (en) 2020-12-31 2022-07-07 Sana Biotechnology, Inc. Methods and compositions for modulating car-t activity
US11401512B2 (en) 2018-02-08 2022-08-02 Sangamo Therapeutics, Inc. Engineered target specific nucleases
US11421007B2 (en) 2018-04-18 2022-08-23 Sangamo Therapeutics, Inc. Zinc finger protein compositions for modulation of huntingtin (Htt)
WO2022189967A1 (en) 2021-03-09 2022-09-15 Crispr Therapeutics Ag Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
WO2022204071A1 (en) 2021-03-22 2022-09-29 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
WO2022216524A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
WO2022216514A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
WO2022216624A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
US11471489B2 (en) 2018-04-05 2022-10-18 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
WO2022235911A1 (en) 2021-05-05 2022-11-10 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for ipsc-derived microglia
US11504389B2 (en) 2016-12-01 2022-11-22 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
WO2022251443A1 (en) 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
WO2022251367A1 (en) 2021-05-27 2022-12-01 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
WO2023287827A2 (en) 2021-07-14 2023-01-19 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
WO2023010135A1 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
WO2023010133A2 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
WO2023019225A2 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
WO2023019203A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Inducible systems for altering gene expression in hypoimmunogenic cells
WO2023019229A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
WO2023019227A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
WO2023039567A2 (en) 2021-09-10 2023-03-16 FUJIFILM Cellular Dynamics, Inc. Compositions of induced pluripotent stem cell-derived cells and methods of use thereof
WO2023042079A1 (en) 2021-09-14 2023-03-23 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
WO2023070019A1 (en) 2021-10-21 2023-04-27 Vertex Pharmaceuticals Incorporated Hypoimmune cells
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
WO2023077050A1 (en) 2021-10-29 2023-05-04 FUJIFILM Cellular Dynamics, Inc. Dopaminergic neurons comprising mutations and methods of use thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
US11655275B2 (en) 2017-05-03 2023-05-23 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US11661611B2 (en) 2017-11-09 2023-05-30 Sangamo Therapeutics, Inc. Genetic modification of cytokine inducible SH2-containing protein (CISH) gene
WO2023105244A1 (en) 2021-12-10 2023-06-15 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
WO2023119201A2 (en) 2021-12-22 2023-06-29 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023122722A1 (en) 2021-12-22 2023-06-29 Sangamo Therapeutics, Inc. Novel zinc finger fusion proteins for nucleobase editing
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
WO2023131637A1 (en) 2022-01-06 2023-07-13 Vib Vzw Improved silage grasses
WO2023131616A1 (en) 2022-01-05 2023-07-13 Vib Vzw Means and methods to increase abiotic stress tolerance in plants
WO2023137471A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
WO2023137472A2 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
WO2023144199A1 (en) 2022-01-26 2023-08-03 Vib Vzw Plants having reduced levels of bitter taste metabolites
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
EP4234570A2 (en) 2018-09-18 2023-08-30 Sangamo Therapeutics, Inc. Programmed cell death 1 (pd1) specific nucleases
WO2023164688A1 (en) 2022-02-28 2023-08-31 Kite Pharma, Inc. Allogeneic therapeutic cells
WO2023166425A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023180968A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
WO2023180904A1 (en) 2022-03-21 2023-09-28 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
WO2023180967A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
WO2023230613A1 (en) 2022-05-27 2023-11-30 The Broad Institute, Inc. Improved mitochondrial base editors and methods for editing mitochondrial dna
US11834686B2 (en) 2018-08-23 2023-12-05 Sangamo Therapeutics, Inc. Engineered target specific base editors
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
WO2023240169A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
WO2023242827A2 (en) 2022-06-17 2023-12-21 Crispr Therapeutics Ag LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY
WO2023248145A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Compositions and methods for treating human immunodeficiency virus
WO2023248147A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Methods and compositions for in vivo editing of stem cells
WO2023250511A2 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
US11857641B2 (en) 2019-02-06 2024-01-02 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type I
WO2024006911A1 (en) 2022-06-29 2024-01-04 FUJIFILM Holdings America Corporation Ipsc-derived astrocytes and methods of use thereof
WO2024003786A1 (en) 2022-06-29 2024-01-04 Crispr Therapeutics Ag Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
WO2024015881A2 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
WO2024013514A2 (en) 2022-07-15 2024-01-18 Pig Improvement Company Uk Limited Gene edited livestock animals having coronavirus resistance
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
WO2024040254A2 (en) 2022-08-19 2024-02-22 Tune Therapeutics, Inc. Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
US11920148B2 (en) 2017-02-22 2024-03-05 Crispr Therapeutics Ag Compositions and methods for gene editing
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
WO2024062388A2 (en) 2022-09-20 2024-03-28 Crispr Therapeutics Ag Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
US11965022B2 (en) 2021-12-23 2024-04-23 Sana Biotechnology, Inc. Methods and compositions for modulating CAR-T activity

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3980447B2 (en) * 2002-08-14 2007-09-26 花王株式会社 Hard surface cleaning composition
JP2004155803A (en) * 2002-11-01 2004-06-03 Kao Corp Solid cleaning agent composition for flush toilet
JP4130387B2 (en) * 2003-07-11 2008-08-06 花王株式会社 Toilet cleaner
JP4271524B2 (en) * 2003-07-11 2009-06-03 花王株式会社 Aqueous liquid composition
JP5342126B2 (en) 2006-10-31 2013-11-13 花王株式会社 Bleach composition
JP5252826B2 (en) * 2007-04-17 2013-07-31 ディバーシー株式会社 Cleaning composition for hard surface
JP5281420B2 (en) * 2009-01-20 2013-09-04 花王株式会社 Liquid detergent composition for hard surfaces
JP5642429B2 (en) * 2010-05-31 2014-12-17 上野製薬株式会社 Cleaning disinfectant composition
JP5769570B2 (en) * 2010-09-28 2015-08-26 小林製薬株式会社 Biofilm remover, biofilm removal composition, and biofilm removal method
JP5705510B2 (en) * 2010-11-25 2015-04-22 大日本除蟲菊株式会社 Acidic antibacterial detergent composition
GB201022132D0 (en) * 2010-12-31 2011-02-02 Byotrol Plc Anti-microbial composition
JP6000514B2 (en) * 2011-03-17 2016-09-28 株式会社Adeka Oil stain cleaning composition
JP5659087B2 (en) * 2011-06-08 2015-01-28 花王株式会社 Liquid detergent composition for hard surfaces
JP5832189B2 (en) * 2011-07-25 2015-12-16 大日本除蟲菊株式会社 Rinsing accelerator for hard surface cleaner
GB2501341B (en) * 2011-12-29 2014-10-22 Byotrol Plc Anti-microbial composition
JP6052957B2 (en) * 2012-07-03 2016-12-27 花王株式会社 Liquid fragrance composition for flush toilet
JP5752220B2 (en) * 2013-12-16 2015-07-22 花王株式会社 Bactericidal detergent composition for hard surfaces
JP6516353B2 (en) * 2014-12-26 2019-05-22 ライオン株式会社 Liquid cleaning agent for bathroom
JP7075655B2 (en) * 2018-03-14 2022-05-26 株式会社ニイタカ Detergent composition, spray bottle, wet wiper and deodorant disinfectant cleaning method
EP3772947A4 (en) 2018-04-09 2021-12-01 Rhodia Operations Compositions and methods for long lasting disinfection
JP2020041074A (en) * 2018-09-12 2020-03-19 ライオン株式会社 Liquid detergent composition for clothing
JP7335068B2 (en) * 2018-12-20 2023-08-29 中国塗料株式会社 Antifouling paint composition, antifouling coating film, substrate with antifouling coating film, antifouling method for substrate, and method for producing substrate with antifouling coating film
JP6700453B1 (en) * 2019-03-22 2020-05-27 株式会社Adeka Hard surface cleaner composition and hard surface cleaning method

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014808A (en) * 1973-06-04 1977-03-29 Tennant Company Detergent composition
EP0311343A2 (en) * 1987-10-09 1989-04-12 The Procter & Gamble Company Toilet composition
EP0342997A2 (en) * 1988-05-20 1989-11-23 Unilever Plc General-purpose cleaning compositions
JPH02145697A (en) * 1988-11-25 1990-06-05 Kao Corp Cleaning agent composition for flush toilet
WO1991000332A1 (en) * 1989-06-23 1991-01-10 Unilever Plc Cleaning composition
JPH07233394A (en) * 1993-12-28 1995-09-05 Kao Corp Cleaner composition for hard surface
JPH09169995A (en) * 1995-12-20 1997-06-30 Kao Corp Stain-proofing cleaning agent composition for toilet
JPH101697A (en) * 1996-06-14 1998-01-06 Kao Corp Detergent composition for toilet
JPH10195498A (en) * 1996-12-27 1998-07-28 Lion Corp Liquid detergent composition
WO1998042815A1 (en) * 1997-03-21 1998-10-01 Unilever Plc Personal cleansing bar with enhanced deposition
WO1999014308A1 (en) * 1997-09-12 1999-03-25 Izabella Bogacka Method of obtaining everyday hygiene agents
JPH11140491A (en) * 1997-09-02 1999-05-25 Kao Corp Bactericidal cleansing agent composition for floor
WO2000022077A1 (en) * 1998-10-13 2000-04-20 The Procter & Gamble Company Laundry detergent compositions with a cationically charged dye maintenance polymer
WO2001042415A1 (en) * 1999-12-08 2001-06-14 Unilever N.V. Use of polymeric material in the treatment of hard surfaces

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014808A (en) * 1973-06-04 1977-03-29 Tennant Company Detergent composition
EP0311343A2 (en) * 1987-10-09 1989-04-12 The Procter & Gamble Company Toilet composition
EP0342997A2 (en) * 1988-05-20 1989-11-23 Unilever Plc General-purpose cleaning compositions
JPH02145697A (en) * 1988-11-25 1990-06-05 Kao Corp Cleaning agent composition for flush toilet
WO1991000332A1 (en) * 1989-06-23 1991-01-10 Unilever Plc Cleaning composition
JPH07233394A (en) * 1993-12-28 1995-09-05 Kao Corp Cleaner composition for hard surface
JPH09169995A (en) * 1995-12-20 1997-06-30 Kao Corp Stain-proofing cleaning agent composition for toilet
JPH101697A (en) * 1996-06-14 1998-01-06 Kao Corp Detergent composition for toilet
JPH10195498A (en) * 1996-12-27 1998-07-28 Lion Corp Liquid detergent composition
WO1998042815A1 (en) * 1997-03-21 1998-10-01 Unilever Plc Personal cleansing bar with enhanced deposition
JPH11140491A (en) * 1997-09-02 1999-05-25 Kao Corp Bactericidal cleansing agent composition for floor
WO1999014308A1 (en) * 1997-09-12 1999-03-25 Izabella Bogacka Method of obtaining everyday hygiene agents
WO2000022077A1 (en) * 1998-10-13 2000-04-20 The Procter & Gamble Company Laundry detergent compositions with a cationically charged dye maintenance polymer
WO2001042415A1 (en) * 1999-12-08 2001-06-14 Unilever N.V. Use of polymeric material in the treatment of hard surfaces

Cited By (491)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501387B2 (en) 2002-02-22 2009-03-10 Kao Corporation Antifouling detergent for hard surfaces
US7544649B2 (en) 2002-02-22 2009-06-09 Kao Corporation Antifouling detergent for hard surfaces
WO2003070866A1 (en) * 2002-02-22 2003-08-28 Kao Corporation Antifouling detergent for hard surfaces
EP2927318A1 (en) 2003-08-08 2015-10-07 Sangamo BioSciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2005014791A2 (en) 2003-08-08 2005-02-17 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP3222715A1 (en) 2003-08-08 2017-09-27 Sangamo BioSciences, Inc. Methods and compositions for targeted cleavage and recombination
US9752140B2 (en) 2003-08-08 2017-09-05 Sangamo Therapeutics, Inc. Methods and compostions for targeted genomic deletion
US9260726B2 (en) 2003-08-08 2016-02-16 Sangamo Biosciences, Inc. Targeted integration and expression on exogenous nucleic acid sequences
US9249428B2 (en) 2003-08-08 2016-02-02 Sangamo Biosciences, Inc. Methods and compositions for targeted genomic deletion
EP2947146A1 (en) 2004-02-05 2015-11-25 Sangamo BioSciences, Inc. Methods and compositions for targeted cleavage and recombination
JP2005232241A (en) * 2004-02-18 2005-09-02 Toyo Aluminium Foil Products Kk Coating agent for removing greasy dirt
US8771986B2 (en) 2004-08-06 2014-07-08 Sangamo Biosciences, Inc. Engineered cleavage half-domains
US8034598B2 (en) 2004-08-06 2011-10-11 Sangamo Biosciences, Inc. Engineered cleavage half-domains
EP2292274A1 (en) 2004-09-16 2011-03-09 Sangamo BioSciences, Inc. Compositions and methods for protein production
US8313925B2 (en) 2005-07-26 2012-11-20 Sangamo Biosciences, Inc. Zinc finger proteins and method for inactivating a dhfr gene in a chinese hamster ovary cell
US9045763B2 (en) 2005-07-26 2015-06-02 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
US9765360B2 (en) 2005-07-26 2017-09-19 Sangamo Therapeutics, Inc. Linear donor constructs for targeted integration
US9376685B2 (en) 2005-07-26 2016-06-28 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
US7914796B2 (en) 2006-05-25 2011-03-29 Sangamo Biosciences, Inc. Engineered cleavage half-domains
EP2213731A1 (en) 2006-05-25 2010-08-04 Sangamo BioSciences, Inc. Variant foki cleavage half-domains
EP2206782A1 (en) 2006-05-25 2010-07-14 Sangamo BioSciences, Inc. Methods and compositions for gene inactivation
US11648267B2 (en) 2006-05-25 2023-05-16 Sangamo Therapeutics, Inc. Methods and compositions for gene inactivation
US8569253B2 (en) 2006-05-25 2013-10-29 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
US9434776B2 (en) 2006-05-25 2016-09-06 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
US7951925B2 (en) * 2006-05-25 2011-05-31 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
US8524221B2 (en) 2006-05-25 2013-09-03 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
EP2765195A1 (en) 2006-05-25 2014-08-13 Sangamo BioSciences, Inc. Methods and compositions for gene inactivation
EP2447279A1 (en) 2006-05-25 2012-05-02 Sangamo BioSciences, Inc. Methods and compositions for gene inactivation
EP2395081A1 (en) 2006-08-11 2011-12-14 Dow AgroSciences LLC Zinc finger nuclease-mediated homologous recombination
US10907175B2 (en) * 2006-11-13 2021-02-02 Sangamo Therapeutics, Inc. Isolated human cell with an inactivated glucocorticoid receptor gene
US11884930B2 (en) 2006-11-13 2024-01-30 Sangamo Biosciences, Inc. Method of inactivating a glucocorticoid receptor gene in an isolated cell
US9217026B2 (en) 2006-11-13 2015-12-22 Sangamo Biosciences, Inc. Method of inactivating a glucocorticoid receptor gene in an isolated cell
US20160076056A1 (en) * 2006-11-13 2016-03-17 Sangamo Biosciences, Inc. Method of inactivating a glucocorticoid receptor gene in an isolated cell
EP2415873A1 (en) 2006-12-14 2012-02-08 Dow AgroSciences LLC Optimized non-canonical zinc finger proteins
EP2412812A1 (en) 2006-12-14 2012-02-01 Dow AgroSciences LLC Optimized non-canonical zinc finger proteins
EP2415872A1 (en) 2006-12-14 2012-02-08 Dow AgroSciences LLC Optimized non-canonical zinc finger proteins
EP3070169A1 (en) 2006-12-14 2016-09-21 Dow AgroSciences LLC Optimized non-canonical zinc finger proteins
US8110379B2 (en) 2007-04-26 2012-02-07 Sangamo Biosciences, Inc. Targeted integration into the PPP1R12C locus
US11649468B2 (en) 2007-04-26 2023-05-16 Sangamo Therapeutics, Inc. Targeted integration into the PPP1R12C locus
US9267154B2 (en) 2007-04-26 2016-02-23 Sangamo Biosciences, Inc. Targeted integration into the PPP1R12C locus
US8822221B2 (en) 2007-04-26 2014-09-02 Sangamo Biosciences, Inc. Targeted integration into the PPP1R12C locus
US9914940B2 (en) 2007-04-26 2018-03-13 Sangamo Therapeutics, Inc. Targeted integration into the PPP1R12C locus
US9322036B2 (en) 2007-07-12 2016-04-26 Sangamo Biosciences, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression
US9890395B2 (en) 2007-07-12 2018-02-13 Sangamo Therapeutics, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression
EP2527435A2 (en) 2007-07-12 2012-11-28 Sangamo BioSciences, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression
US7919313B2 (en) 2007-07-12 2011-04-05 Sangamo Biosciences, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression
US8772025B2 (en) 2007-07-12 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
US10046028B2 (en) 2007-09-27 2018-08-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US9506120B2 (en) 2007-09-27 2016-11-29 Sangamo Biosciences, Inc. Rapid in vivo identification of biologically active nucleases
US8889390B2 (en) 2007-09-27 2014-11-18 Dow Agrosciences Llc Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
US10344289B2 (en) 2007-09-27 2019-07-09 Dow Agrosciences Llc Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
US8399218B2 (en) 2007-09-27 2013-03-19 Dow Agrosciences, Llc Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
US9402879B2 (en) 2007-09-27 2016-08-02 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
US9121072B2 (en) 2007-09-27 2015-09-01 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
EP3072973A1 (en) 2007-09-27 2016-09-28 Dow AgroSciences LLC Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
US9115409B2 (en) 2007-09-27 2015-08-25 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
EP2597155A1 (en) 2007-10-25 2013-05-29 Sangamo BioSciences, Inc. Methods and compositions for targeted integration
US8936936B2 (en) 2007-10-25 2015-01-20 Sangamo Biosciences, Inc. Methods and compositions for targeted integration
EP2936976A1 (en) 2008-04-21 2015-10-28 Danziger Innovations Ltd. Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
US11608492B2 (en) 2008-05-28 2023-03-21 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
US10822599B2 (en) 2008-05-28 2020-11-03 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
US9982245B2 (en) 2008-05-28 2018-05-29 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
US9394531B2 (en) 2008-05-28 2016-07-19 Sangamo Biosciences, Inc. Compositions for linking DNA-binding domains and cleavage domains
EP2910568A2 (en) 2008-06-10 2015-08-26 Sangamo BioSciences, Inc. Methods and compositions for generation of BAX- and BAK-deficient cell lines
WO2009151591A2 (en) 2008-06-10 2009-12-17 Sangamo Biosciences, Inc. Methods and compositions for generation of bax- and bak-deficient cell lines
US8597912B2 (en) 2008-06-10 2013-12-03 Sangamo Biosciences, Inc. Methods and compositions for generation of Bax-and Bak-deficient cell lines
US10689717B2 (en) 2008-08-22 2020-06-23 Sangamo Therapeutics, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
US10113207B2 (en) 2008-08-22 2018-10-30 Sangamo Therapeutics, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
EP2789691A1 (en) 2008-08-22 2014-10-15 Sangamo BioSciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
US9631186B2 (en) 2008-08-22 2017-04-25 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
WO2010021692A1 (en) 2008-08-22 2010-02-25 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
US11149321B2 (en) 2008-08-22 2021-10-19 Sangamo Therapeutics, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
US9200266B2 (en) 2008-08-22 2015-12-01 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
US8703489B2 (en) 2008-08-22 2014-04-22 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
US9388426B2 (en) 2008-10-29 2016-07-12 Sangamo Biosciences, Inc. Methods and compositions for inactivating glutamine synthetase gene expression
US8153399B2 (en) 2008-10-29 2012-04-10 Sangamo Biosciences, Inc. Methods and compositions for inactivating glutamine synthetase gene expression
US9206404B2 (en) 2008-12-04 2015-12-08 Sangamo Biosciences, Inc. Method of deleting an IgM gene in an isolated rat cell
EP3156494A1 (en) 2008-12-04 2017-04-19 Sangamo BioSciences, Inc. Genome editing in rats using zinc-finger nucleases
WO2010065123A1 (en) 2008-12-04 2010-06-10 Sangamo Biosciences, Inc. Genome editing in rats using zinc-finger nucleases
US8329986B2 (en) 2008-12-17 2012-12-11 Dow Agrosciences, Llc Targeted integration into the Zp15 locus
WO2010077319A1 (en) 2008-12-17 2010-07-08 Dow Agrosciences Llc Targeted integration into the zp15 locus
WO2010090744A1 (en) 2009-02-04 2010-08-12 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathies
EP3354275A1 (en) 2009-02-04 2018-08-01 Sangamo Therapeutics, Inc. Methods and compositions for treating neuropathies
US8551945B2 (en) 2009-02-04 2013-10-08 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathies
US9717759B2 (en) 2009-03-20 2017-08-01 Sangamo Therapeutics, Inc. Modification of CXCR4 using engineered zinc finger proteins
US8871905B2 (en) 2009-03-20 2014-10-28 Sangamo Biosciences, Inc. Modification of CXCR4 using engineered zinc finger proteins
US9834787B2 (en) 2009-04-09 2017-12-05 Sangamo Therapeutics, Inc. Targeted integration into stem cells
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
US8772009B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2011002503A1 (en) 2009-06-30 2011-01-06 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
EP2727600A1 (en) 2009-07-28 2014-05-07 Sangamo BioSciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
US9943565B2 (en) 2009-07-28 2018-04-17 Sangamo Therapeutics, Inc. Methods and compositions for treating trinucleotide repeat disorders
US10646543B2 (en) 2009-07-28 2020-05-12 Sangamo Therapeutics, Inc. Methods and compositions for treating trinucleotide repeat disorders
US9234016B2 (en) 2009-07-28 2016-01-12 Sangamo Biosciences, Inc. Engineered zinc finger proteins for treating trinucleotide repeat disorders
EP3156504A1 (en) 2009-08-11 2017-04-19 Sangamo BioSciences, Inc. Organisms homozygous for targeted modification
US10827731B2 (en) 2009-08-11 2020-11-10 Sangamo Therapeutics, Inc. Method of inactivating the IPK1 gene in corn
EP3428289A1 (en) 2009-08-11 2019-01-16 Sangamo Therapeutics, Inc. Organisms homozygous for targeted modification
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
US9631201B2 (en) 2009-10-22 2017-04-25 Sangamo Biosciences, Inc. Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
US10017775B2 (en) 2009-10-22 2018-07-10 Dow Agrosciences Llc Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
EP2722392A2 (en) 2009-10-22 2014-04-23 Dow AgroSciences LLC Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
US8592645B2 (en) 2009-10-22 2013-11-26 Dow Agrosciences Llc Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
US10155011B2 (en) 2009-11-10 2018-12-18 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US11439666B2 (en) 2009-11-10 2022-09-13 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US10260062B2 (en) 2010-01-22 2019-04-16 Sangamo Therapeutics, Inc. Targeted genomic alteration
US8623618B2 (en) 2010-02-08 2014-01-07 Sangamo Biosciences, Inc. Engineered cleavage half-domains
US10066242B2 (en) 2010-02-08 2018-09-04 Sangamo Therapeutics, Inc. Artificial nucleases comprising engineered cleavage half-domains
EP3594333A1 (en) 2010-02-08 2020-01-15 Sangamo Therapeutics, Inc. Engineered cleavage half-domains
US10640790B2 (en) 2010-02-08 2020-05-05 Sangamo Therapeutics, Inc. Artificial nucleases including engineered FokI cleavage half-domains
EP2615106A1 (en) 2010-02-08 2013-07-17 Sangamo BioSciences, Inc. Engineered cleavage half-domains
US11725218B2 (en) 2010-02-08 2023-08-15 Sangamo Therapeutics, Inc. Artificial nucleases comprising engineered cleavage half-domains
US9150879B2 (en) 2010-02-08 2015-10-06 Sangamo Biosciences, Inc. Engineered cleavage half-domains
EP4328304A2 (en) 2010-02-08 2024-02-28 Sangamo Therapeutics, Inc. Engineered cleavage half-domains
US9376689B2 (en) 2010-02-08 2016-06-28 Sangamo Biosciences, Inc. Engineered cleavage half-domains
US8962281B2 (en) 2010-02-08 2015-02-24 Sangamo Biosciences, Inc. Engineered cleavage half-domains
US11136599B2 (en) 2010-02-08 2021-10-05 Sangamo Therapeutics, Inc. Artifical nucleases comprising engineered cleavage half-domains
US9765361B2 (en) 2010-02-08 2017-09-19 Sangamo Therapeutics, Inc. Engineered cleavage half-domains for generating nuclease-mediated genomic modifications in a cell
EP2660318A1 (en) 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US9005973B2 (en) 2010-02-09 2015-04-14 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US9970028B2 (en) 2010-02-09 2018-05-15 Sangamo Therapeutics, Inc. Targeted genomic modification with partially single-stranded donor molecules
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
US8771985B2 (en) 2010-04-26 2014-07-08 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using zinc-finger nucleases
EP3636766A1 (en) 2010-05-03 2020-04-15 Sangamo Therapeutics, Inc. Compositions for linking zinc finger modules
US9163245B2 (en) 2010-05-03 2015-10-20 Sangamo Biosciences, Inc. Compositions for linking zinc finger modules
US8772453B2 (en) 2010-05-03 2014-07-08 Sangamo Biosciences, Inc. Compositions for linking zinc finger modules
US10858416B2 (en) 2010-07-21 2020-12-08 Sangamo Therapeutics, Inc. Methods and compositions for modification of a HLA locus
US10072062B2 (en) 2010-07-21 2018-09-11 Sangamo Therapeutics, Inc. Methods and compositions for modification of a HLA locus
WO2012012667A2 (en) 2010-07-21 2012-01-26 Sangamo Biosciences, Inc. Methods and compositions for modification of a hla locus
US8945868B2 (en) 2010-07-21 2015-02-03 Sangamo Biosciences, Inc. Methods and compositions for modification of a HLA locus
EP3511420A1 (en) 2010-09-27 2019-07-17 Sangamo Therapeutics, Inc. Methods and compositions for inhibiting viral entry into cells
WO2012047598A1 (en) 2010-09-27 2012-04-12 Sangamo Biosciences, Inc. Methods and compositions for inhibiting viral entry into cells
US9566352B2 (en) 2010-09-27 2017-02-14 Sangamo Biosciences, Inc. Methods and compositions for inhibiting viral entry into cells
US9629930B2 (en) 2010-10-12 2017-04-25 Sangamo Biosciences, Inc. Methods and compositions for treating hemophilia B
US9175280B2 (en) 2010-10-12 2015-11-03 Sangamo Biosciences, Inc. Methods and compositions for treating hemophilia B
WO2012051343A1 (en) 2010-10-12 2012-04-19 The Children's Hospital Of Philadelphia Methods and compositions for treating hemophilia b
EP3311822A1 (en) 2010-11-17 2018-04-25 Sangamo Therapeutics, Inc. Methods and compositions for modulating pd1
US9267123B2 (en) 2011-01-05 2016-02-23 Sangamo Biosciences, Inc. Methods and compositions for gene correction
US9631187B2 (en) 2011-01-05 2017-04-25 Sangamo Biosciences, Inc. Methods and compositions for gene correction
US9161995B2 (en) 2011-07-25 2015-10-20 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
US9150847B2 (en) 2011-09-21 2015-10-06 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
EP3498833A1 (en) 2011-09-21 2019-06-19 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
WO2013044008A2 (en) 2011-09-21 2013-03-28 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
US9394545B2 (en) 2011-09-21 2016-07-19 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
US10975375B2 (en) 2011-09-21 2021-04-13 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
US11639504B2 (en) 2011-09-21 2023-05-02 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
US11859190B2 (en) 2011-09-21 2024-01-02 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
US9777281B2 (en) 2011-09-21 2017-10-03 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
US8895264B2 (en) 2011-10-27 2014-11-25 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
US9222105B2 (en) 2011-10-27 2015-12-29 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
US9458205B2 (en) 2011-11-16 2016-10-04 Sangamo Biosciences, Inc. Modified DNA-binding proteins and uses thereof
US9499597B2 (en) 2012-02-29 2016-11-22 Sangamo Biosciences, Inc. Methods and compositions for treating Huntington's disease
US8841260B2 (en) 2012-02-29 2014-09-23 Sangamo Biosciences, Inc. Methods and compositions for treating Huntington's Disease
US11723952B2 (en) 2012-02-29 2023-08-15 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
WO2013130824A1 (en) 2012-02-29 2013-09-06 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
US10471123B2 (en) 2012-02-29 2019-11-12 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's disease
US10857203B2 (en) 2012-02-29 2020-12-08 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's disease
US10265377B2 (en) 2012-02-29 2019-04-23 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
EP3839050A2 (en) 2012-04-18 2021-06-23 The Board of Trustees of the Leland Stanford Junior University Non-disruptive gene targeting
WO2013166315A1 (en) 2012-05-02 2013-11-07 Dow Agrosciences Llc Targeted modification of malate dehydrogenase
US10358684B2 (en) 2012-05-02 2019-07-23 Dow Agrosciences Llc Targeted modification of malate dehydrogenase
US11085092B2 (en) 2012-05-02 2021-08-10 Corteva Agriscience Llc Targeted modification of malate dehydrogenase
US9523098B2 (en) 2012-05-02 2016-12-20 Dow Agrosciences Llc Targeted modification of malate dehydrogenase
US10174331B2 (en) 2012-05-07 2019-01-08 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
WO2013169802A1 (en) 2012-05-07 2013-11-14 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
EP3444342A1 (en) 2012-07-11 2019-02-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of lysosomal storage diseases
US9877988B2 (en) 2012-07-11 2018-01-30 Sangamo Therapeutics, Inc. Method of treating lysosomal storage diseases using nucleases and a transgene
US11898158B2 (en) 2012-07-11 2024-02-13 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of lysosomal storage diseases
US10293000B2 (en) 2012-07-11 2019-05-21 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of lysosomal storage diseases
WO2014011901A2 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
EP3196301A1 (en) 2012-07-11 2017-07-26 Sangamo BioSciences, Inc. Methods and compositions for the treatment of monogenic diseases
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
US11040115B2 (en) 2012-07-11 2021-06-22 Sangamo Therapeutics, Inc. Method for the treatment of lysosomal storage diseases
EP3816281A1 (en) 2012-07-11 2021-05-05 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of lysosomal storage diseases
US9956247B2 (en) 2012-07-11 2018-05-01 Sangamo Therapeutics, Inc. Method of treating lysosomal storage diseases
US10883119B2 (en) 2012-07-11 2021-01-05 Sangamo Therapeutics, Inc. Methods and compositions for delivery of biologics
WO2014011237A1 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
US9963715B2 (en) 2012-08-29 2018-05-08 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
US11492643B2 (en) 2012-08-29 2022-11-08 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
WO2014036219A2 (en) 2012-08-29 2014-03-06 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
US9650648B2 (en) 2012-08-29 2017-05-16 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
EP3404099A1 (en) 2012-09-07 2018-11-21 Dow AgroSciences LLC Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US9963711B2 (en) 2012-09-07 2018-05-08 Sangamo Therapeutics, Inc. FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US9914930B2 (en) 2012-09-07 2018-03-13 Dow Agrosciences Llc FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
EP3431600A1 (en) 2012-09-07 2019-01-23 Dow AgroSciences LLC Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
WO2014039692A2 (en) 2012-09-07 2014-03-13 Dow Agrosciences Llc Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
EP3406715A1 (en) 2012-09-07 2018-11-28 Dow AgroSciences LLC Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US9493779B2 (en) 2012-09-07 2016-11-15 Dow Agrosciences Llc FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
WO2014039872A1 (en) 2012-09-07 2014-03-13 Dow Agrosciences Llc Engineered transgene integration platform (etip) for gene targeting and trait stacking
US10844389B2 (en) 2012-09-07 2020-11-24 Dow Agrosciences Llc FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
WO2014039702A2 (en) 2012-09-07 2014-03-13 Dow Agrosciences Llc Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US10577616B2 (en) 2012-09-07 2020-03-03 Dow Agrosciences Llc FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US10961540B2 (en) 2012-09-07 2021-03-30 Dow Agrosciences Llc FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US10287595B2 (en) 2012-09-07 2019-05-14 Dow Agrosciences Llc Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US10526610B2 (en) 2012-09-07 2020-01-07 Dow Agrosciences Llc FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
US11236175B2 (en) 2012-10-10 2022-02-01 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US9597357B2 (en) 2012-10-10 2017-03-21 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
EP3763810A2 (en) 2012-10-10 2021-01-13 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
US9255250B2 (en) 2012-12-05 2016-02-09 Sangamo Bioscience, Inc. Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene
US10415046B2 (en) 2012-12-13 2019-09-17 Dow Agrosciences Llc Precision gene targeting to a particular locus in maize
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
WO2014130955A1 (en) 2013-02-25 2014-08-28 Sangamo Biosciences, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
US10918668B2 (en) 2013-03-21 2021-02-16 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
US11198883B2 (en) 2013-04-05 2021-12-14 Dow Agrosciences Llc Methods and compositions for integration of an exogenous sequence within the genome of plants
US10501748B2 (en) 2013-04-05 2019-12-10 Dow Agrosciences Llc Methods and compositions for integration of an exogenous sequence within the genome of plants
WO2014165612A2 (en) 2013-04-05 2014-10-09 Dow Agrosciences Llc Methods and compositions for integration of an exogenous sequence within the genome of plants
EP3679785A2 (en) 2013-04-05 2020-07-15 Dow AgroSciences LLC Methods and compositions for integration of an exogenous sequence within the genome of plants
US10196652B2 (en) 2013-05-15 2019-02-05 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
US9873894B2 (en) 2013-05-15 2018-01-23 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
US10196651B2 (en) 2013-05-15 2019-02-05 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
US9902974B2 (en) 2013-05-15 2018-02-27 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
EP3730615A2 (en) 2013-05-15 2020-10-28 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
EP3591045A1 (en) 2013-08-28 2020-01-08 Sangamo Therapeutics, Inc. Compositions for linking dna-binding domains and cleavage domains
EP3988654A1 (en) 2013-08-28 2022-04-27 Sangamo Therapeutics, Inc. Compositions for linking dna-binding domains and cleavage domains
US9567609B2 (en) 2013-08-28 2017-02-14 Sangamo Biosciences, Inc. Compositions for linking DNA-binding domains and cleavage domains
WO2015031619A1 (en) 2013-08-28 2015-03-05 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
US11041174B2 (en) 2013-08-28 2021-06-22 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
US10538787B2 (en) 2013-08-28 2020-01-21 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
US9957526B2 (en) 2013-10-17 2018-05-01 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US10117899B2 (en) 2013-10-17 2018-11-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
WO2015057980A1 (en) 2013-10-17 2015-04-23 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US10494648B2 (en) 2013-10-17 2019-12-03 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2015057976A1 (en) 2013-10-17 2015-04-23 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
EP3441468A2 (en) 2013-10-17 2019-02-13 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2015066638A2 (en) 2013-11-04 2015-05-07 Dow Agrosciences Llc Optimal maize loci
EP3862434A1 (en) 2013-11-04 2021-08-11 Dow AgroSciences LLC Optimal soybean loci
US11098317B2 (en) 2013-11-04 2021-08-24 Corteva Agriscience Llc Optimal maize loci
US11098316B2 (en) 2013-11-04 2021-08-24 Corteva Agriscience Llc Optimal soybean loci
US10233465B2 (en) 2013-11-04 2019-03-19 Dow Agrosciences Llc Optimal soybean loci
US11149287B2 (en) 2013-11-04 2021-10-19 Corteva Agriscience Llc Optimal soybean loci
WO2015066636A2 (en) 2013-11-04 2015-05-07 Dow Agrosciences Llc Optimal maize loci
US11198882B2 (en) 2013-11-04 2021-12-14 Corteva Agriscience Llc Optimal maize loci
US10273493B2 (en) 2013-11-04 2019-04-30 Dow Agrosciences Llc Optimal maize loci
US9909131B2 (en) 2013-11-04 2018-03-06 Dow Agrosciences Llc Optimal soybean loci
US10106804B2 (en) 2013-11-04 2018-10-23 Dow Agrosciences Llc Optimal soybean loci
WO2015066643A1 (en) 2013-11-04 2015-05-07 Dow Agrosciences Llc Optimal soybean loci
US10093940B2 (en) 2013-11-04 2018-10-09 Dow Agrosciences Llc Optimal maize loci
WO2015070212A1 (en) 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
US10369201B2 (en) 2013-11-11 2019-08-06 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's disease
US11021696B2 (en) 2013-11-13 2021-06-01 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
EP3492593A1 (en) 2013-11-13 2019-06-05 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
US10407476B2 (en) 2013-12-09 2019-09-10 Sangamo Therapeutics, Inc. Methods and compositions for treating hemophilia
US11634463B2 (en) 2013-12-09 2023-04-25 Sangamo Therapeutics, Inc. Methods and compositions for treating hemophilia
US10081661B2 (en) 2013-12-09 2018-09-25 Sangamo Therapeutics, Inc. Methods and compositions for genome engineering
US9771403B2 (en) 2013-12-09 2017-09-26 Sangamo Therapeutics, Inc. Methods and compositions for treating hemophilia
US10968261B2 (en) 2013-12-09 2021-04-06 Sangamo Therapeutics, Inc. Methods and compositions for genome engineering
EP3757116A1 (en) 2013-12-09 2020-12-30 Sangamo Therapeutics, Inc. Methods and compositions for genome engineering
US10072066B2 (en) 2014-02-03 2018-09-11 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a beta thalessemia
WO2015117081A2 (en) 2014-02-03 2015-08-06 Sangamo Biosciences, Inc. Methods and compositions for treatment of a beta thalessemia
US10370680B2 (en) 2014-02-24 2019-08-06 Sangamo Therapeutics, Inc. Method of treating factor IX deficiency using nuclease-mediated targeted integration
US11591622B2 (en) 2014-02-24 2023-02-28 Sangamo Therapeutics, Inc. Method of making and using mammalian liver cells for treating hemophilia or lysosomal storage disorder
WO2015130931A1 (en) 2014-02-28 2015-09-03 Dow Agrosciences Llc Root specific expression conferred by chimeric gene regulatory elements
US9624498B2 (en) 2014-03-18 2017-04-18 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
EP3929279A1 (en) 2014-03-18 2021-12-29 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression
WO2015143046A2 (en) 2014-03-18 2015-09-24 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
US10612041B2 (en) 2014-03-21 2020-04-07 The Board Of Trustees Of The Leland Stanford Junior University Genome editing without nucleases
US10507232B2 (en) 2014-04-02 2019-12-17 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
US11110154B2 (en) 2014-05-08 2021-09-07 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's Disease
US9574211B2 (en) 2014-05-13 2017-02-21 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
US9970001B2 (en) 2014-06-05 2018-05-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease design
WO2016005449A1 (en) 2014-07-08 2016-01-14 Vib Vzw Means and methods to increase plant yield
WO2016011029A2 (en) 2014-07-14 2016-01-21 Washington State University Nanos knock-out that ablates germline cells
EP4335926A2 (en) 2014-07-14 2024-03-13 Washington State University Nanos knock-out that ablates germline cells
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2016011381A1 (en) 2014-07-18 2016-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells
US9816074B2 (en) 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
US9757420B2 (en) 2014-07-25 2017-09-12 Sangamo Therapeutics, Inc. Gene editing for HIV gene therapy
US9833479B2 (en) 2014-07-30 2017-12-05 Sangamo Therapeutics, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
US10435677B2 (en) 2014-09-16 2019-10-08 Sangamo Therapeutics, Inc. Genetically modified human cell with a corrected mutant sickle cell mutation
WO2016044416A1 (en) 2014-09-16 2016-03-24 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
EP3878948A1 (en) 2014-09-16 2021-09-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
WO2016118726A2 (en) 2015-01-21 2016-07-28 Sangamo Biosciences, Inc. Methods and compositions for identification of highly specific nucleases
US11634688B2 (en) 2015-01-26 2023-04-25 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US11155796B2 (en) 2015-02-09 2021-10-26 Duke University Compositions and methods for epigenome editing
WO2016161446A1 (en) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2017176806A1 (en) 2015-04-03 2017-10-12 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b cells
EP4335918A2 (en) 2015-04-03 2024-03-13 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2016168230A2 (en) 2015-04-15 2016-10-20 Dow Agrosciences Llc Plant promoter for transgene expression
WO2016168229A1 (en) 2015-04-15 2016-10-20 Dow Agrosciences Llc Plant promoter for transgene expression
WO2016178207A1 (en) 2015-05-04 2016-11-10 Ramot At Tel-Aviv University Ltd. Methods and kits for fragmenting dna
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
US10808020B2 (en) 2015-05-12 2020-10-20 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
WO2016196388A1 (en) 2015-05-29 2016-12-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
US10619154B2 (en) 2015-06-18 2020-04-14 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
WO2017011519A1 (en) 2015-07-13 2017-01-19 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US10450585B2 (en) 2015-07-13 2019-10-22 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US10786533B2 (en) 2015-07-15 2020-09-29 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2017023570A1 (en) 2015-08-06 2017-02-09 The Curators Of The University Of Missouri Pathogen-resistant animals having modified cd163 genes
WO2017053164A1 (en) 2015-09-22 2017-03-30 Dow Agrosciences Llc Plant promoter and 3' utr for transgene expression
WO2017180180A2 (en) 2015-09-22 2017-10-19 Dow Agrosciences Llc Plant promoter and 3' utr for transgene expression
US11123443B2 (en) 2015-09-23 2021-09-21 Sangamo Therapeutics, Inc. Htt repressors and uses thereof
US10435441B2 (en) 2015-09-23 2019-10-08 Sangamo Therapeutics, Inc. HTT repressors and uses thereof
WO2017070298A1 (en) 2015-10-22 2017-04-27 Dow Agrosciences Llc Plant promoter for transgene expression
US11072781B2 (en) 2015-11-04 2021-07-27 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US10287606B2 (en) 2015-11-04 2019-05-14 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US10858628B2 (en) 2015-11-04 2020-12-08 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
EP4249074A2 (en) 2015-11-04 2023-09-27 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US11352607B2 (en) 2015-11-04 2022-06-07 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
WO2017079673A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US11162076B2 (en) 2015-11-04 2021-11-02 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US10947505B2 (en) 2015-11-04 2021-03-16 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
WO2017078935A1 (en) 2015-11-04 2017-05-11 Dow Agrosciences Llc Plant promoter for transgene expression
US11162075B2 (en) 2015-11-04 2021-11-02 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US11793888B2 (en) 2015-11-23 2023-10-24 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
US10639383B2 (en) 2015-11-23 2020-05-05 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
US11285175B2 (en) 2015-12-18 2022-03-29 Sangamo Therapeutics, Inc. Targeted disruption of the MHC cell receptor
WO2017106528A2 (en) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the t cell receptor
WO2017106537A2 (en) 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the mhc cell receptor
US11352631B2 (en) 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
US10500229B2 (en) 2015-12-18 2019-12-10 Sangamo Therapeutics, Inc. Targeted disruption of the MHC cell receptor
WO2017123757A1 (en) 2016-01-15 2017-07-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
US10724020B2 (en) 2016-02-02 2020-07-28 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
US11920169B2 (en) 2016-02-02 2024-03-05 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
EP3769775A2 (en) 2016-02-02 2021-01-27 Sangamo Therapeutics, Inc. Compositions for linking dna-binding domains and cleavage domains
WO2017165655A1 (en) 2016-03-23 2017-09-28 Dana-Farber Cancer Institute, Inc. Methods for enhancing the efficiency of gene editing
US11421218B2 (en) 2016-03-23 2022-08-23 Dana-Farber Cancer Institute, Inc. Methods for enhancing the efficiency of gene editing
WO2018005559A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
EP3992632A1 (en) 2016-06-27 2022-05-04 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
WO2018005556A1 (en) 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
WO2018013840A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
EP4219462A1 (en) 2016-07-13 2023-08-02 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
EP3838287A2 (en) 2016-07-27 2021-06-23 Case Western Reserve University Compounds and methods of promoting myelination
WO2018029034A1 (en) 2016-08-09 2018-02-15 Vib Vzw Cellulose synthase inhibitors and mutant plants
EP3995574A1 (en) 2016-08-24 2022-05-11 Sangamo Therapeutics, Inc. Regulation of gene expression using engineered nucleases
US10975393B2 (en) 2016-08-24 2021-04-13 Sangamo Therapeutics, Inc. Engineered target specific nucleases
WO2018039448A1 (en) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Engineered target specific nucleases
US11827900B2 (en) 2016-08-24 2023-11-28 Sangamo Therapeutics, Inc. Engineered target specific nucleases
US10563184B2 (en) 2016-08-24 2020-02-18 Sangamo Therapeutics, Inc. Regulation of gene expression using engineered nucleases
EP3964573A1 (en) 2016-08-24 2022-03-09 Sangamo Therapeutics, Inc. Engineered target specific nucleases
WO2018039440A1 (en) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Regulation of gene expression using engineered nucleases
US11845965B2 (en) 2016-08-24 2023-12-19 Sangamo Therapeutics, Inc. Regulation of gene expression using engineered nucleases
US10960085B2 (en) 2016-09-07 2021-03-30 Sangamo Therapeutics, Inc. Modulation of liver genes
WO2018067264A1 (en) 2016-10-03 2018-04-12 Dow Agrosciences Llc Plant promoter for transgene expression
WO2018067618A1 (en) 2016-10-03 2018-04-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2018067265A1 (en) 2016-10-03 2018-04-12 Dow Agrosciences Llc Plant promoter for transgene expression
US11072660B2 (en) 2016-10-03 2021-07-27 Juno Therapeutics, Inc. HPV-specific binding molecules
WO2018067826A1 (en) 2016-10-05 2018-04-12 Cellular Dynamics International, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
WO2018071873A2 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
US11896615B2 (en) 2016-10-13 2024-02-13 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
EP4190335A1 (en) 2016-10-13 2023-06-07 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
US11219695B2 (en) 2016-10-20 2022-01-11 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of Fabry disease
US11020492B2 (en) 2016-10-31 2021-06-01 Sangamo Therapeutics, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
WO2018081775A1 (en) 2016-10-31 2018-05-03 Sangamo Therapeutics, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
US11504389B2 (en) 2016-12-01 2022-11-22 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
US11793833B2 (en) 2016-12-02 2023-10-24 Juno Therapeutics, Inc. Engineered B cells and related compositions and methods
WO2018102612A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
WO2018106732A1 (en) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
EP4276187A2 (en) 2016-12-08 2023-11-15 Case Western Reserve University Methods and compositions for enhancing functional myelin production
WO2018106782A1 (en) 2016-12-08 2018-06-14 Case Western Reserve University Methods and compositions for enhancing functional myelin production
US11920148B2 (en) 2017-02-22 2024-03-05 Crispr Therapeutics Ag Compositions and methods for gene editing
WO2018195418A1 (en) 2017-04-20 2018-10-25 Oregon Health & Science University Human gene correction
US11655275B2 (en) 2017-05-03 2023-05-23 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
EP4215543A2 (en) 2017-10-03 2023-07-26 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2019070541A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. Hpv-specific binding molecules
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
US11661611B2 (en) 2017-11-09 2023-05-30 Sangamo Therapeutics, Inc. Genetic modification of cytokine inducible SH2-containing protein (CISH) gene
US10927346B2 (en) 2017-12-22 2021-02-23 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof
EP4083192A1 (en) 2017-12-22 2022-11-02 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof
US11365394B2 (en) 2017-12-22 2022-06-21 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof
WO2019143678A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2019143675A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2019143677A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
US11401512B2 (en) 2018-02-08 2022-08-02 Sangamo Therapeutics, Inc. Engineered target specific nucleases
WO2019191495A1 (en) 2018-03-29 2019-10-03 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
WO2019195492A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
US11471489B2 (en) 2018-04-05 2022-10-18 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
WO2019195491A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
US11421007B2 (en) 2018-04-18 2022-08-23 Sangamo Therapeutics, Inc. Zinc finger protein compositions for modulation of huntingtin (Htt)
WO2019215500A1 (en) 2018-05-11 2019-11-14 Crispr Therapeutics Ag Methods and compositions for treating cancer
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2019234141A1 (en) 2018-06-06 2019-12-12 Vib Vzw NOVEL MUTANT PLANT CINNAMOYL-CoA REDUCTASE PROTEINS
WO2019234750A1 (en) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Methods of regenerating and transforming cannabis
WO2019234754A1 (en) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Nucleic acid constructs and methods of using same
US11834686B2 (en) 2018-08-23 2023-12-05 Sangamo Therapeutics, Inc. Engineered target specific base editors
EP4234570A2 (en) 2018-09-18 2023-08-30 Sangamo Therapeutics, Inc. Programmed cell death 1 (pd1) specific nucleases
WO2020095248A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-ptk7 immune cell cancer therapy
WO2020095249A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-liv1 immune cell cancer therapy
WO2020095107A1 (en) 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
WO2020118073A1 (en) 2018-12-05 2020-06-11 Vertex Pharmaceuticals Incorporated Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene
GB201820109D0 (en) 2018-12-11 2019-01-23 Vib Vzw Plants with a lignin trait and udp-glycosyltransferase mutation
US11453639B2 (en) 2019-01-11 2022-09-27 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
US11857641B2 (en) 2019-02-06 2024-01-02 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type I
WO2020185628A1 (en) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Cd40l compositions and methods for tunable regulation
WO2020205838A1 (en) 2019-04-02 2020-10-08 Sangamo Therapeutics, Inc. Methods for the treatment of beta-thalassemia
WO2020219726A1 (en) 2019-04-23 2020-10-29 Sangamo Therapeutics, Inc. Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
WO2020223535A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
WO2020223571A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
WO2020261219A1 (en) 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
WO2021022223A1 (en) 2019-08-01 2021-02-04 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
WO2021041316A1 (en) 2019-08-23 2021-03-04 Sana Biotechnology, Inc. Cd24 expressing cells and uses thereof
WO2021044378A1 (en) 2019-09-06 2021-03-11 Crispr Therapeutics Ag Genetically engineered t cells having improved persistence in culture
WO2021067871A1 (en) 2019-10-02 2021-04-08 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for repressing alpha-synuclein expression
WO2021067864A1 (en) 2019-10-02 2021-04-08 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for treatment of prion disease
WO2021087361A1 (en) 2019-11-01 2021-05-06 Sangamo Therapeutics, Inc. Zinc finger nuclease variants for treating or preventing lysosomal storage diseases
WO2021087358A1 (en) 2019-11-01 2021-05-06 Sangamo Therapeutics, Inc. Gin recombinase variants
WO2021087366A1 (en) 2019-11-01 2021-05-06 Sangamo Therapeutics, Inc. Compositions and methods for genome engineering
WO2021142376A1 (en) 2020-01-08 2021-07-15 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
WO2021151012A1 (en) 2020-01-22 2021-07-29 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for repressing tau expression
WO2021155065A1 (en) 2020-01-28 2021-08-05 The Broad Institute, Inc. Base editors, compositions, and methods for modifying the mitochondrial genome
WO2021195426A1 (en) 2020-03-25 2021-09-30 Sana Biotechnology, Inc. Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
WO2021224416A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
WO2021224395A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
WO2021231661A2 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
WO2021236852A1 (en) 2020-05-20 2021-11-25 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
WO2022036150A1 (en) 2020-08-13 2022-02-17 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
WO2022046760A2 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
WO2022064428A1 (en) 2020-09-23 2022-03-31 Crispr Therapeutics Ag Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence
WO2022067122A1 (en) 2020-09-25 2022-03-31 Sangamo Therapeutics, Inc. Zinc finger fusion proteins for nucleobase editing
WO2022072826A1 (en) 2020-10-02 2022-04-07 Sangamo Therapeutics, Inc. Novel zinc finger protein transcription factors for repressing alpha-synuclein expression
WO2022098787A1 (en) 2020-11-04 2022-05-12 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
WO2022101641A1 (en) 2020-11-16 2022-05-19 Pig Improvement Company Uk Limited Influenza a-resistant animals having edited anp32 genes
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022120334A1 (en) 2020-12-03 2022-06-09 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
WO2022137181A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
WO2022146891A2 (en) 2020-12-31 2022-07-07 Sana Biotechnology, Inc. Methods and compositions for modulating car-t activity
US11802157B2 (en) 2020-12-31 2023-10-31 Sana Biotechnology, Inc. Methods and compositions for modulating CAR-T activity
WO2022189967A1 (en) 2021-03-09 2022-09-15 Crispr Therapeutics Ag Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
WO2022204071A1 (en) 2021-03-22 2022-09-29 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
WO2022216624A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
WO2022216514A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
WO2022216524A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
WO2022235911A1 (en) 2021-05-05 2022-11-10 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for ipsc-derived microglia
WO2022251443A1 (en) 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
WO2022251367A1 (en) 2021-05-27 2022-12-01 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
WO2023287827A2 (en) 2021-07-14 2023-01-19 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
WO2023010135A1 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
WO2023010133A2 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
WO2023019203A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Inducible systems for altering gene expression in hypoimmunogenic cells
WO2023019227A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
WO2023019225A2 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023019229A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
WO2023039567A2 (en) 2021-09-10 2023-03-16 FUJIFILM Cellular Dynamics, Inc. Compositions of induced pluripotent stem cell-derived cells and methods of use thereof
WO2023042079A1 (en) 2021-09-14 2023-03-23 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
WO2023070019A1 (en) 2021-10-21 2023-04-27 Vertex Pharmaceuticals Incorporated Hypoimmune cells
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
WO2023077050A1 (en) 2021-10-29 2023-05-04 FUJIFILM Cellular Dynamics, Inc. Dopaminergic neurons comprising mutations and methods of use thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2023105244A1 (en) 2021-12-10 2023-06-15 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
WO2023119201A2 (en) 2021-12-22 2023-06-29 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
WO2023122722A1 (en) 2021-12-22 2023-06-29 Sangamo Therapeutics, Inc. Novel zinc finger fusion proteins for nucleobase editing
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
US11965022B2 (en) 2021-12-23 2024-04-23 Sana Biotechnology, Inc. Methods and compositions for modulating CAR-T activity
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
WO2023131616A1 (en) 2022-01-05 2023-07-13 Vib Vzw Means and methods to increase abiotic stress tolerance in plants
WO2023131637A1 (en) 2022-01-06 2023-07-13 Vib Vzw Improved silage grasses
WO2023137471A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
WO2023137472A2 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
WO2023144199A1 (en) 2022-01-26 2023-08-03 Vib Vzw Plants having reduced levels of bitter taste metabolites
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023164688A1 (en) 2022-02-28 2023-08-31 Kite Pharma, Inc. Allogeneic therapeutic cells
WO2023166425A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023180904A1 (en) 2022-03-21 2023-09-28 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
WO2023180967A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
WO2023180968A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
WO2023230613A1 (en) 2022-05-27 2023-11-30 The Broad Institute, Inc. Improved mitochondrial base editors and methods for editing mitochondrial dna
WO2023240169A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2023242827A2 (en) 2022-06-17 2023-12-21 Crispr Therapeutics Ag LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY
WO2023248145A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Compositions and methods for treating human immunodeficiency virus
WO2023248147A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Methods and compositions for in vivo editing of stem cells
WO2023250511A2 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
WO2024003786A1 (en) 2022-06-29 2024-01-04 Crispr Therapeutics Ag Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
WO2024006911A1 (en) 2022-06-29 2024-01-04 FUJIFILM Holdings America Corporation Ipsc-derived astrocytes and methods of use thereof
WO2024015881A2 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
WO2024013514A2 (en) 2022-07-15 2024-01-18 Pig Improvement Company Uk Limited Gene edited livestock animals having coronavirus resistance
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
WO2024040254A2 (en) 2022-08-19 2024-02-22 Tune Therapeutics, Inc. Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
WO2024062388A2 (en) 2022-09-20 2024-03-28 Crispr Therapeutics Ag Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20

Also Published As

Publication number Publication date
TWI283267B (en) 2007-07-01
JP2002060786A (en) 2002-02-26

Similar Documents

Publication Publication Date Title
WO2002016536A1 (en) Bactericidal antifouling detergent for hard surface
JP2003096493A (en) Germicidal antifouling detergent for rigid surface
JP2020147586A (en) Disinfectant composition containing quaternary ammonium compounds
USRE44058E1 (en) Cleaning composition comprising a water-soluble or water-dispersible polymer
JP5818546B2 (en) Antibacterial agent
US6395698B1 (en) Corrosion resistant sanitizing/disinfecting cleaning and wood preservative formulation
JP4907327B2 (en) Detergent composition for dishwasher
CN110591833B (en) Toilet cleaning agent and preparation method thereof
CN117050817A (en) Antimicrobial multipurpose cleaners and methods of making and using the same
JP3422978B2 (en) Cleaning composition for hard surfaces
US7544649B2 (en) Antifouling detergent for hard surfaces
JP2003238991A (en) Stainproofing detergent for hard surface
JP3617813B2 (en) Cleaning composition for hard surface
JP4008364B2 (en) Antifouling cleaner for hard surfaces
JP7315948B2 (en) Disinfectant detergent composition
JP5926482B2 (en) Biofilm removing agent and biofilm removing composition
JP2004315691A (en) Germicidal detergent composition
JP4781664B2 (en) Antibacterial agent
JP2009149858A (en) Cleaning agent composition for hard surface
JP3986846B2 (en) Concentrated liquid detergent for flush toilet
JP4912859B2 (en) Dishwasher finish composition
JP3198079B2 (en) Solid cleaning composition for hard surfaces
JP3558907B2 (en) Hard surface antifouling antibacterial detergent composition
JP3405970B2 (en) Cleaning composition for hard surfaces
JP2012092320A (en) Biofilm removing agent, composition for removing biofilm, and method for removing biofilm

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CN US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase